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ABSTRACT 
 
Background: Overtreatment of localized prostate cancer (PCa) is a concern as many 
men die of other causes prior to experiencing a treatment benefit. This dissertation 
characterizes the need for assessing other cause mortality (OCM) risk in older men with 
PCa and informs efforts to identify patients most likely to benefit from definitive PCa 
treatment. 
Methods: Using the linked Surveillance Epidemiology and End Results-Medicare Health 
Outcomes Survey database, 2,931 men (mean age=75) newly diagnosed with clinical 
stage T1a-T3a PCa from 1998-2009 were identified. Survival analysis methods were 
used to compare observed 10-year OCM by primary treatment type. Age and health 
factors predictive of primary treatment type were assessed with multinomial logistic 
regression. Predicted mortality estimates from Social Security life tables (recommended 
for life expectancy evaluation) and two OCM risk estimation tools were compared to 
observed rates. An improved OCM prediction model was developed fitting Fine and Gray 
competing risks models for 10-year OCM with age, sociodemographic, comorbidity, 
activities of daily living, and patient-reported health data as predictors. The tools’ ability 
to discriminate between patients who died and those who did not was evaluated with 
Harrell’s c-index (range 0.5-1), which also guided new model selection.   
Results: Fifty-four percent of older men with localized PCa underwent radiotherapy 
while 13% underwent prostatectomy. Twenty-three percent of those treated with 
radiotherapy and 12% of those undergoing prostatectomy experienced OCM within 10 
years of treatment and thus were considered overtreated. Health factors indicative of a 
shorter life expectancy (increased comorbidity, worse physical health, smoking) had little 
to no association with radiotherapy assignment but were significantly related to 
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reductions in the likelihood of undergoing prostatectomy. Social Security life tables 
overestimated mortality risk and discriminated poorly between men who died and those 
who did not over 10 years (c-index=0.59). Existing OCM risk estimation tools were less 
likely to overestimate OCM rates and had limited but improved discrimination (c-
index=0.64). A risk model developed with self-reported age, Charlson comorbidity index 
score, overall health (excellent-good/fair/poor), smoking, and marital status predictors 
had improved discrimination (c-index=0.70). 
Conclusions: Overtreatment of older men with PCa is primarily attributable to 
radiotherapy and may be reduced by pretreatment assessment of mortality-related 
health factors. This dissertation provides a prognostic model which utilizes a set of five 
self-reported characteristics that better identify patients likely to die of OCM within 10 
years of diagnosis than age and comorbidity-based assessments alone. 
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CHAPTER I: INTRODUCTION 
 
Prostate cancer (PCa) is the most common non-skin cancer in American men; 
nearly one in six men are diagnosed over a lifetime.1 Despite the high incidence of PCa, 
less than 16% of those diagnosed will die of their cancer; the vast majority of men with 
PCa ultimately die from other causes.2,3 This is largely due to two factors; first, most men 
are diagnosed with PCa over the age of 65, and second, the majority of new PCa 
diagnoses (81%) are for lower-risk tumors that are confined to the prostate and tend to 
have a relatively indolent course.4,5 Furthermore, randomized clinical trial data 
demonstrate a lack of treatment benefit over follow-up periods less than 8-10 years, 
when compared to conservatively managed controls.6 Thus, guidelines recommend that 
clinicians routinely consider life expectancy when recommending management 
strategies for clinically localized PCa and that definitive treatments only be considered if 
overall life expectancy is >10 years.7–9  
For men with prostate-confined tumors, the average risk of dying of PCa in the 
10 years following diagnosis is less than 5%, regardless of treatment.10,11 In contrast, the 
risk of dying of other non-PCa causes in 10 years can range from just 6% to over 90% 
depending on an individual’s age, health, and social factors.10,12–15 Thus, accurate 
assessment of 10-year life expectancy, and particularly the risk of dying of non-prostate 
causes, is essential for promoting appropriate treatment decision-making for men with 
PCa.  
Current Utilization of Life Expectancy Evaluation in Clinical Practice 
 Despite recommendations to routinely consider life expectancy in treatment 
decision-making for men with PCa less than 23% of PCa specialists in the U.S. utilize 
tools to estimate 10-year mortality risk.16 This is a uniquely low utilization rate given that, 
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in contrast, over 80% of prostate cancer specialists rely on tools to classify the risk of 
prostate tumor recurrence.16 The limited utilization of mortality risk estimation tools may 
be attributable to the lack of validated and endorsed methods for evaluating other cause 
mortality (OCM) risk.17 Formal evaluations of the performance of these tools are needed 
to promote and inform clinical adoption.  
 Without the use of prediction tools, clinicians’ independent estimates of life 
expectancy are often inaccurate.18–20 In the absence of standardized routine 
consideration of mortality risk many patients likely receive definitive treatments only to 
go on to die of other causes within the 10 years following PCa treatment. These men 
likely do not experience any survival benefit from their PCa treatment and are thus 
considered overtreated. 
The Problem of Prostate Cancer Overtreatment 
 Studies increasingly present evidence of the overtreatment of patients with low-
risk prostate cancer and have suggested that substantial percentages of patients receive 
definitive therapies who ultimately die of other causes in less than 10-years.12–15,21,22 
Available PCa management options can broadly be categorized into definitive (e.g., 
surgical or radiation therapies) or conservative management strategies (e.g., watchful 
waiting or active surveillance). Definitive treatments are provided with curative intent, 
and include radical prostatectomy, a surgical procedure which can be performed with 
open surgery, laparoscopy, or with robotic laparoscopy. There are also radiation 
therapies that include external beam radiation or brachytherapy. These definitive 
therapies are, however, often associated with side effects that can impair quality of life.23 
Thus, for individuals who are unlikely to experience any survival benefit from treatment 
of low to moderate-risk tumors, surgical or radiation therapies may result in harm. 
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However, more accurate life-expectancy evaluation is also critical for the few individuals 
who are undertreated for PCa, sometimes simply due to their age alone.21 Better 
assessment of OCM risk will enable more appropriate allocation of treatment, improving 
both over and undertreatment. 
Studies evaluating patient-level health factors and assignment to PCa therapies 
have demonstrated that factors such as comorbidity may not influence allocation to 
definitive therapy.14 However, there has been some indication that radical prostatectomy 
is less likely to be offered to patients with higher comorbidity burden.21 Recent work has 
supported a potential differential effect in the impact of age and comorbidity on 
radiotherapy and radical prostatectomy assignment.24 Developing an improved 
understanding of the life expectancy-related health factors that currently influence 
treatment assignment is of high importance for identifying areas for improving patient 
selection for definitive therapy.  Understanding how these factors may differently affect 
the likelihood of undergoing radiation or radical prostatectomy will help in providing 
tailored interventions for reducing overtreatment of PCa.  
As overtreatment of PCa may be a heterogeneous phenomenon, understanding 
the extent to which the mainstays of therapy (radiation and radical prostatectomy) 
individually contribute to overtreatment is important. That older patients tend to receive 
radiotherapy more often than radical prostatectomy suggests there may be differences in 
the rates of overtreatment between these two treatment modalities.12,21,24 Better 
characterization of these differences will provide high priority areas of intervention for 
improving patient selection for PCa treatment.  
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Current Risk Calculation Tools for Predicting Mortality in Prostate Cancer  
The National Comprehensive Cancer Network guidelines have recommended 
that clinicians utilize the Social Security life tables for evaluating overall life expectancy 
in patients diagnosed with PCa.9,25 These life tables are based on data from males in the 
general US population and provide a simple age-based assessment of overall life 
expectancy. Overall life expectancy, however, is only a proxy for estimating OCM risk. 
While the Social Security life tables have been endorsed for overall life expectancy 
estimation, whether they provide accurate and clinically useful mortality estimates in 
men with localized PCa requires investigation.  
Ideally, risk estimation tools would provide personalized, separate estimates of 
the risk of OCM that could be compared to the risk of dying of PCa-specific mortality 
(PCSM), which would allow patients to weigh the competing risks side-by-side.26 To 
address this need tools have been developed to specifically estimate OCM risk in men 
with PCa. Currently, two nomograms (visual aids for estimating patient risk based on a 
limited of patient characteristics) are available for clinical use in specifically predicting 
the risk of OCM in patients with PCa.26,27 There are also two life tables (look-up tables 
that classify patients into general risk categories) for OCM risk estimation.10,12 While 
several risk estimation tools exist for evaluating OCM risk (Table 1.1), these tools require 
validation and no tools have been endorsed for clinical use.17,28 Further, whether these 
OCM risk estimation tools, developed in populations of men with localized PCa, can 
provide improved estimates over Social Security life tables has yet to be determined.  
Predictors of Other Cause Mortality in Prostate Cancer 
A growing body of literature has evaluated predictors of OCM for patients with 
PCa. Evidence consistently demonstrates that older age and a higher comorbidity 
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burden are strongly predictive of OCM.10,12,26,29–33 Specified either as simple counts or 
weighted indices, such as the Charlson Comorbidity Index (CCI), comorbidity plays an 
important role in OCM prediction.29,34 However, age and comorbidity alone are not 
complete determinants of mortality risk. 
Studies of the Cancer of the Prostate Strategic Urologic Research Endeavor 
(CaPSURE) and Prostate Cancer Outcomes Study databases (PCOS) have suggested 
there is value in incorporating sociodemographic and patient-reported health measures 
in OCM prediction models.27,33 Variables such as education level, marriage and race 
have been associated with OCM risk.26,27,33 Additionally, smoking is an important health 
behavior associated with OCM risk.33 Among patient-reported measures of health, there 
is broad evidence to support the use of simple single-item self-ratings of health (SRH) 
from excellent to poor,20,27,35–37 as well as more complex patient-reported measures of 
functional health and well-being, such as the Short Form-36 Health Survey (SF-36) for 
mortality risk estimation.20,33,37–41 These self-ratings of health have been well validated in 
heterogeneous populations, including the Medicare managed care population and in 
patients with varying levels of comorbidities.42–46 The SF-36 Physical Component 
Summary (PCS) score and its subdomains have been consistently associated with 
mortality in heterogeneous settings over a variety of time spans from 1 month to 10 
years.37–39,47 
While these many factors serve as important predictors of OCM in separate 
models, no prediction tool has yet to incorporate these elements into a single model. 
Such a comprehensive prediction tool may provide meaningful improvements in the 
accuracy of risk predictions and the ability to distinguish patients who are likely to die of 
OCM within 10-years and those likely to survive.   
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Specific Aims 
This dissertation aims to characterize the need for OCM risk estimation in older 
men newly diagnosed with localized PCa and aims to inform efforts to better identify 
older patients who would most likely benefit from aggressive treatment vs. those who 
may not, as they may be more likely to die of OCM. This work utilized data from the 
linked Surveillance Epidemiology and End Results - Medicare Health Outcomes Study 
(SEER-MHOS) database which contains detailed cancer and treatment information, 
cause of death, comorbidities, patient-reported physical and mental health, activities of 
daily living, and sociodemographic data on 19,727 men, mostly age 65 and older, 
undergoing all types of PCa management in diverse regions of the United States.48 This 
dataset enables characterization of overtreatment of PCa among older American men, 
as well as evaluation of and improvement upon the performance of OCM prediction tools 
using statistical techniques to assess predictive model performance. It also supports the 
development of a novel prediction tool that better predicts personalized risk of 10-year 
OCM.49,50 Specific aims of this dissertation are:  
Aim 1. Define the extent of PCa overtreatment by treatment type and assess factors 
associated with assignment to particular treatment modalities among older men. 
1.1 Explore observed rates of 10-year OCM by definitive PCa treatment type. 
1.2 Explore whether age and health factors, predictive of dying of OCM, predict 
receipt of primary surgery or radiotherapy for prostate cancer in older 
American men. 
Aim 2. Evaluate the performance of two tools for estimating 10-year OCM risk against 
Social Security life table estimates, which guidelines currently recommend for life-
expectancy estimation.  
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2.1 Evaluate the accuracy of mortality risk estimates vs. observed mortality rates 
in the SEER-MHOS data. 
2.2 Evaluate the risk estimation tools’ ability to discriminate between individuals 
in the SEER-MHOS data who die and those who do not. 
Aim 3. Develop an improved prediction model for 10-year OCM risk utilizing an efficient 
combination of self-reported data from men newly diagnosed with localized prostate 
cancer. 
3.1 Build a new model with improved discrimination between those who die of 
OCM and those who do not, exploring combinations of age, comorbidity, 
patient-reported health, smoking, and sociodemographic predictors, including 
effect modification by patient-reported health, comorbid conditions, and 
smoking. 
3.2  Create a prototype risk calculation tool to enable estimation of individualized 
10-year OCM risk.  
 
 
C
hapter I                
 
8 
Table 1.1: Previously published prediction models for other cause mortality and all-cause mortality risk for men with PCa and 
availability as a risk estimation tool 
Publication First 
Author Outcome Estimated Predictors 
Clinical Tool Available 
Kutikov26 10-year OCM  
 Age at diagnosis 
 Comorbidity count 
 Treatment with radiotherapy vs. radical 
prostatectomy 
 Receipt of androgen deprivation therapy 
 Race (black vs. white) 
Nomogram for 10-year OCM risk 
Daskivich12,30,31 10-year OCM  
 Age at diagnosis 
 Charlson Comorbidity Index score or comorbidity 
count 
Two separate life tables for 10-
year OCM risk estimation 
Hoffman27,* 10-year OCM  
 Age at diagnosis 
 Self-rated general health (excellent/v. 
good/good/fair-poor) 
 Race/ethnicity (Hispanic vs. white vs. black) 
Nomogram for 10-year OCM risk 
Simone33 5-year OCM  
 Age >65 at diagnosis 
 SF-36 Physical Function ½ standard deviation below 
age-adjusted norm 
 Other malignancy at diagnosis 
 Smoker at diagnosis 
 Education level high school or less 
 High D’Amico risk group 
None 
Social Security 
Administration25 
10-year all-cause 
mortality  Age 
Life tables and annual risk of all-
cause mortality by age 
Walz51  10-year all-cause mortality 
 Age at therapy 
 Charlson Comorbidity Index score 
Nomogram for  
10-year all-cause mortality 
Tewari52  10-year non-PCa mortality 
 Age at diagnosis 
 Charlson Comorbidity Index Score 2 or more 
 Income in $10,000s 
 Radical prostatectomy 
Life-tables for  
10-year all-cause mortality 
OCM= other cause mortality 
Nomograms are visual aids for graphically estimating risk scores; they convert equations to visual aids for calculating risk scores 
Lifetables provide risk-estimates in the form of look-up tables and can account for a limited set of patient characteristics 
*The Hoffman nomogram was published during the writing phase of this dissertation and thus is only briefly evaluated in Chapter IV of this dissertation 
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CHAPTER II: DEFINING THE EXTENT AND NATURE OF PROSTATE 
CANCER OVERTREATMENT IN OLDER MEN 
 
ABSTRACT 
Objective: To better characterize the extent of prostate cancer (PCa) overtreatment 
among older American men by reporting 10-year other cause mortality (OCM) rates after 
primary surgical or radiotherapy and to assess health factors predictive of treatment 
modality.  
Methods: Using the linked Surveillance Epidemiology and End Results-Medicare Health 
Outcomes Survey database, men newly diagnosed with clinical stage T1a-T3a PCa from 
1998-2009 were selected. Observed cumulative incidence of 10-year OCM was 
compared across men treated with radical prostatectomy, radiotherapy (brachytherapy/ 
external-beam radiation), and conservatively managed men. Predictors of primary 
treatment, including age, Charlson Comorbidity Index (CCI) score, patient-reported 
physical health, and smoking status, were assessed using multinomial logistic 
regression, adjusted for D’Amico risk score, county-level radical prostatectomy rates, 
year of diagnosis, education, and race. 
Results: Of 2,425 men (median age=73), 13% underwent radical prostatectomy and 
54% underwent radiotherapy. Observed 10-year cumulative incidence of OCM among 
radical prostatectomy, radiotherapy, and conservatively managed patients was 12%, 
23%, and 31%, respectively. Men of increasing age, CCI score, worse physical health, 
and smokers were less likely to undergo radical prostatectomy (p<0.05), yet only 
increasing age was associated with reduced odds of radiotherapy after multivariable 
adjustment.  
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Conclusions: While most older men with localized PCa undergo radiotherapy as 
primary treatment for their disease, nearly a quarter of these men are overtreated. In 
comparison, overtreatment is less common with radical prostatectomy, as patients with 
worse overall health are much less likely to receive surgery. There may be substantial 
benefit to improving patient selection for radiotherapies through increased pretreatment 
consideration of patients’ comorbidities and physical health.  
 
INTRODUCTION 
Despite the high incidence of prostate cancer (PCa) in the U.S., the majority of 
men are diagnosed with low-risk tumors and die of other causes.2 Studies increasingly 
present evidence of the overtreatment of patients with low-risk PCa and have suggested 
that roughly half of older men with multiple comorbidities and limited life expectancies 
may be overtreated.12–15 This study aims to better characterize the extent to which 
definitive therapies, namely radical prostatectomy and radiotherapies, contribute to the 
problem of overtreatment.  While older patients are more likely to receive 
radiotherapies,12 it has yet to be determined whether these patients are more likely to be 
overtreated than patients electing to undergo prostatectomy. 
To reduce overtreatment, patients must be more carefully assessed before 
undergoing primary definitive PCa therapies.17 Guidelines recommend that clinicians 
reserve definitive therapy for patients with at least a 10-year life expectancy as there is 
limited evidence for treatment benefit for individuals with shorter life expectancies.7,9,53 
Patients dying of other non-PCa causes within 10 years of a definitive primary treatment 
are thus generally considered overtreated. Despite guideline recommendations, only 
23% of PCa specialists use currently available tools for estimating patients’ life 
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expectancies,16 suggesting that clinicians may not systematically assess their patients’ 
health status and life expectancies when guiding therapeutic decisions.  
As a prerequisite to improving patient selection for treatment, our understanding 
of the current impact of patient-level health factors on treatment assignment must be 
improved. Prior population-based studies suggest that factors such as comorbidity 
burden have not meaningfully influenced patients’ receipt of definitive PCa therapies.12,13 
Characterizing systematic differences in the extent to which health factors predict receipt 
of radical prostatectomy versus radiotherapies for PCa will aid in identifying health 
factors that can be emphasized for improving treatment decisions.  
This population-based study sought to better characterize the extent of PCa 
overtreatment by determining 10-year other cause mortality (OCM) rates by treatment 
type. In addition, this study assessed whether age and important health-related factors 
predict the receipt of primary radical prostatectomy or radiotherapy among older 
American men.  
  
METHODS 
Data Source 
Data were obtained from the Surveillance, Epidemiology, and End Results- 
Medicare Health Outcomes Survey (SEER-MHOS) linked database available through 
permission from the National Cancer Institute.48 The SEER program’s regional registries 
collect sociodemographic, tumor, and treatment data representative of 26% of the U.S. 
population.54 The Centers for Medicare & Medicaid Services (CMS) annually surveys a 
sample of Medicare managed care participants (19% of all Medicare beneficiaries) to 
collect self-reported functional health and wellbeing, comorbidity, and health behavior 
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data with response rates ranging from 64-72%.48 From 1998-2011 over 1.6 million 
Medicare enrollees completed MHOS surveys.55  SEER and MHOS databases were 
linked through a collaboration between the National Cancer Institute and CMS with 
details previously described.48 Follow-up survival data were available through SEER until 
February 2013. 
Study Population  
Eligible participants were aged <80 when newly diagnosed with PCa between 
January 1, 1998 and December 31, 2009, and completed an MHOS survey within the 3 
years preceding their PCa diagnosis. The population was restricted those aged <80 at 
diagnosis as this study intended to evaluate the impact of health factors on treatment 
assignment among older patients, but for whom age alone may not have ruled out 
aggressive therapy; few men over age 80 have a life expectancy greater than 10 
years.12 Patients diagnosed with PCa on autopsy or death certificate or with regionalized 
or metastasized tumors (clinical stage >T3a) were excluded.  
For the analysis of predictors of treatment assignment, the population was limited 
to men diagnosed after January 1, 2004 as data on PSA values and Gleason scoring, 
necessary for more accurate risk stratification of tumors, was only available after this 
date in SEER.  
Outcome Ascertainment 
Survival data and primary cause of death were ascertained through the SEER 
dataset. Patients not alive at last follow-up were classified as having died of PCa-specific 
or other non-prostate causes using the SEER cause of death recode variable (codpub). 
Patients who did not die within 10 years of PCa diagnosis were censored at 10 years if 
followed ≥10 years after diagnosis, or at time of last SEER follow-up if followed <10 
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years. Survival time was calculated from the date of diagnosis until the date of death, or 
censored at date of last SEER follow-up.  
SEER collects treatment information on patients’ primary treatment for PCa. 
Patients who underwent radical prostatectomy were considered to have received 
primary surgical therapy and patients undergoing brachytherapy, external beam 
radiation, or a combination of the two were classified as having received primary 
radiotherapy. Patients who underwent radical prostatectomy and additionally underwent 
some form of radiotherapy were classified as having received primary radical 
prostatectomy. Treatment variables in the SEER database have been validated against 
Medicare claims in patients with PCa, demonstrating >85% sensitivity and >94% 
specificity for radiotherapies and >86% agreement with Medicare data for receipt of 
surgical therapies.56,57 Patients not receiving these primary therapies were considered 
conservatively managed, which may have included active surveillance, watchful waiting, 
and androgen deprivation therapy (all not documented in SEER), as well as any 
alternatives to mainstream definitive therapies (e.g. cryotherapy), although these 
alternatives were rarely administered.  
Data Collection 
Specific health factors were selected from previously developed prediction 
models for estimating life expectancy or non-PCa mortality risk (Table 1.1); these 
included age at diagnosis, Charlson Comorbidity Index (CCI) score, patient-reported 
physical health, and smoking status. A CCI score was approximated using Charlson 
weights for 8 self-reported conditions in the MHOS (myocardial infarction, congestive 
heart failure, stroke, chronic obstructive pulmonary disease, diabetes, inflammatory 
bowel disease/ulcer, paralysis, other cancer), which are included in the CCI.34 Self-
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reported physical health was measured with the Physical Component Summary (PCS) 
score derived from two health-related quality of life surveys included in the MHOS: the 
SF-36 Health Survey (v1)42,43 for men surveyed before 2006, and the VR-12 Health 
Survey58 for men surveyed in 2006 and after. PCS scores were provided by MHOS and 
used a scoring algorithm that maximized comparability of scores across different survey 
forms.59 Scores are normalized to a mean of 50 points in the general U.S. population 
with a standard deviation of 10 points, with higher scores representing better health.60 
Self-reported current smoking status (every day or some days) was determined from 
MHOS. Individuals who had unknown smoking status were categorized as non-smokers, 
as exploratory analyses revealed they experienced survival similar to non-smokers.  
Education was categorized as “more than a high school education” or “high school 
education or less” to provide consistency with prior definitions.33 Race, reported in 
SEER, was categorized as white, black, Hispanic, Asian/Pacific Islander, and other. 
SEER extent of disease (EOD) codes were utilized to identify tumors as clinical 
stage cT1, cT2, cT1/T2 or cT3a (for tumors 2004 and later). Tumor grade was 
characterized as well, moderately, or poorly differentiated. For patients diagnosed after 
January 1, 2004, D’Amico tumor risk group was assigned using clinical T-stage, pre-
diagnosis PSA level, and Gleason score.61 Patients missing one or more data elements 
for D’Amico risk stratification were assigned to the highest risk category based on 
available data, as these patients have similar tumor characteristics to those with 
complete SEER data.62 Adjustment for regional variations in rates of administered 
definitive therapy, considered an important potential factor influencing treatment 
assignment, was achieved by accounting for the ratio of county-level radical 
prostatectomy rates from the Dartmouth Atlas of Health Care to the national average, 
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averaged over the period 2004-2007.63 When county-specific information was not 
available, state-level radical prostatectomy rates were substituted. Subjects were 
matched to their SEER county of cancer diagnosis.  
Statistical Analysis 
Observed cumulative incidence distributions for 10-year non-PCa death, 
accounting for the competing risk of prostate-specific mortality, were calculated for 
radical prostatectomy, radiotherapy, and conservatively managed groups.64 A 
multinomial logistic regression model was fitted with treatment allocation as the outcome 
(conservative management [reference group] vs. radical prostatectomy vs. radiation 
therapy) and the age and health factor covariates listed above as predictors.65 Models 
were adjusted for individuals’ D’Amico risk group, Dartmouth Atlas ratio of county-level 
to national rate of prostatectomy, year of diagnosis, race, and education level, as these 
factors may influence the decision to undergo definitive therapy. The complete case 
method was used.  
Several sensitivity analyses were performed to assess the robustness of the 
analyses. First, a multilevel multinomial logistic model was utilized to account for the 
clustering of observations within counties.65 Second, the model was restricted to 
subjects with low and intermediate D’Amico risk tumors to assess for potential bias 
introduced by including individuals with high D’Amico risk tumors. Additionally, the 
cumulative incidence distributions of 10-year OCM by treatment type were recalculated 
including patients >80 years of age to assess potential underestimation of OCM rates. 
All reported p-values are two sided and a p-value of <0.05 was considered statistically 
significant. Analyses were performed with Stata 12 and SAS 9.3 software.  
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  IRB exemption for this study was obtained from the University of Massachusetts 
Medical School and all work was performed under a data use agreement with the 
National Cancer Institute.   
 
RESULTS 
 Of the 19,727 patients with PCa in the SEER-MHOS database, 2,245 eligible 
patients were identified as having newly diagnosed cT1a-cT3a PCa from January 1, 
1998 - December 31, 2009, and having completed an MHOS survey within 3 years 
preceding their PCa diagnosis. A subset of 1,316 patients diagnosed from January 1, 
2004 - December 31, 2009 was identified for analysis of predictors of treatment 
assignment. Patient characteristics are detailed in Table 2.1, with characteristics of the 
smaller subset in Table 2.2. The majority (67%) of patients received primary definitive 
treatment during the observation period, with 13% of the total population receiving 
radical prostatectomy, and 54% receiving external beam radiation, brachytherapy, or a 
combination of these radiotherapies. Patients had a median age of 73 (IQR: 70-76) at 
diagnosis, with a broad range in comorbidity (CCI range: 0-7), and physical health (PCS 
range: 8-62) scores. 
 Observed cumulative incidence of 10-year OCM among radical prostatectomy, 
radiotherapy, and conservatively managed patients was 12%, 23%, and 31%, 
respectively. Figure 2.1 demonstrates the relationship between receipt of definitive 
therapies and increasing comorbidity burden and physical health. 
 All age and health factors were strongly associated with radical prostatectomy 
allocation, but relationships were weaker and often non-significant for radiotherapy 
(Table 2.3). Patients were significantly less likely to undergo both radical prostatectomy 
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and radiotherapies with each increasing year of age, but the association between age 
and prostatectomy was much larger than with radiotherapies (29% vs. 11% lower odds 
of treatment per year of age).  
The studied health factors were negatively associated with the odds of 
undergoing radical prostatectomy. For each additional CCI point, patients had 39% lower 
odds of undergoing radical prostatectomy vs. conservative management. For every 10 
points lower physical health patients had 34% lower odds of undergoing radical 
prostatectomy, while smokers were 54% less likely to undergo radical prostatectomy 
compared to conservative management. Higher CCI, worse physical health, and 
smoking were not associated with the odds of receiving radiotherapies (Table 2.3).  
Patients with intermediate and high D’Amico risk tumors had over 3-and 20-fold 
increased odds of undergoing radical prostatectomy versus conservative management, 
respectively, as compared to patients with low D’Amico risk tumors; D’Amico tumor risk 
had weaker associations with undergoing radiotherapy (Table 2.3). Patients who were 
diagnosed with PCa in counties where radical prostatectomy is conducted at twice the 
national rate were almost twice as likely to receive prostatectomy versus conservative 
management. Conversely, patients were 45% less likely to receive radiotherapy versus 
conservative management in counties where radical prostatectomy was twice the 
national rate (Table 2.3).  
 Findings remained substantially similar in the sensitivity analyses. After 
accounting for clustering of observations within county, model estimates were nearly 
identical to the primary analysis (Table 2.4). When the model was restricted to low and 
intermediate D’Amico risk patients, physical health had slightly weaker estimated 
association with receipt of radical prostatectomy and had a slightly stronger, statistically 
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significant, association with receiving radiotherapy (15% reduced odds of undergoing 
radiotherapy for 10 points lower PCS) (Table 2.5). Ten-year OCM rates also remained 
nearly identical for radical prostatectomy (12%) and radiotherapy (24%) treated patients 
when patients >80 years of age at diagnosis were included in the analysis (Supplement 
2.A). 
  
DISCUSSION 
 This study sought to assess rates of PCa overtreatment among older men 
treated with radical prostatectomy or radiotherapy and to characterize the impact of 
health factors on the likelihood of receiving these therapies. In this population of older 
American men, overtreatment of PCa was far more likely among radiotherapy than 
radical prostatectomy treated patients. Most men were treated with radiotherapy (54%) 
and nearly a quarter of these men died from non-prostate causes within 10 years, 
suggesting considerable overtreatment. In comparison, only 12% of radical 
prostatectomy treated men died of non-PCa causes over the 10 years following 
treatment. Further, while indicators of worse health were associated with a reduced 
likelihood of surgery, they did not predict a reduced likelihood of undergoing radiation 
treatments. These findings suggest systematic differences in the rates of overtreatment 
as well as factors associated with treatment selection between surgical and 
radiotherapies. Less frequent consideration of health factors prior to radiotherapy may 
contribute to higher overtreatment rates among these patients.  
 The large negative impact of worsening health factors on the likelihood of 
undergoing prostatectomy, combined with the relatively low estimated 12% rate of 
overtreatment suggests there may be less room for improving the selection of patients 
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for surgical therapy. In contrast, there may be substantial benefit to emphasizing 
improvement of patient selection for radiotherapies, the most common treatment 
modality among older men. Furthermore, these findings are consistent with a recent 
study from the distinct SEER-Medicare database, which reported increasing age and 
comorbidity strongly reduced the likelihood of receiving radical prostatectomy for PCa 
but similarly found a lack of negative association between increasing comorbidity burden 
and radiotherapy assignment.24 
This assessment of the extent of overtreatment for men with localized PCa 
yielded lower rates than previously reported in U.S. population-based cohorts.12,15,22 
Nonetheless, overtreatment rates remained substantial among radiotherapy treated 
patients, but were encouragingly much lower among radical prostatectomy treated 
patients. Restricting the analysis to those age <80 at diagnosis did not appear to explain 
the lower overtreatment rates reported here; 10-year OCM rates remained nearly 
identical for radical prostatectomy and radiotherapy treated patients in sensitivity 
analyses that included patients >80 years of age (Supplement 2.A).  In contrast to this 
study, prior analyses of overtreatment have relied on predictions of mortality risk, 
potentially over predicting mortality, while this study used survival analysis methods to 
report the observed cumulative incidence of mortality.12,15   Additionally, Medicare 
managed care participants are slightly healthier with lower mortality risk than similar 
aged Medicare fee-for-service patients, potentially reducing 10-year mortality rates, and 
thus the estimates of overtreatment reported here.66 Furthermore, reports of 10-year 
OCM rates from a cohort of patients exclusively treated with radical prostatectomy in 
Europe, have revealed very similar observed 10-year OCM rates to that reported here 
for men undergoing prostatectomy.67 
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Most clinicians would expect that patients receiving radiotherapy for PCa are 
older, have higher comorbidity burden, and worse physical health than surgically treated 
patients, as they are likely less robust surgical candidates. However, regardless of 
treatment modality life expectancy should influence the treatment decision-making 
process. Yet, there were no significant relationships between health factors and 
radiotherapy assignment.   It should be noted that in the sensitivity analysis of only 
patients with low/intermediate D’Amico risk tumors, physical health had a small, but 
significant negative influence on radiotherapy assignment. However, comorbidity burden 
and smoking status continued to have no association with radiotherapy assignment in 
sensitivity analysis.  
  Targeted policy and research interventions may be needed to improve decision-
making surrounding radiotherapy assignment for PCa. Increased consideration of 
comorbidity burden, physical functioning, and smoking history, factors which currently 
have little association with receipt of radiotherapy, may improve patient selection. 
Decision aids may be a mechanism for promoting consideration of these factors, but 
existing tools have yet to incorporate individualized considerations of life expectancy.68 
Furthermore, available nomograms for estimating life expectancy require improvement 
and may not be reliable enough for individual patient-level decision making.69  
Treatment decision-making is complex, and many factors influence treatment 
assignment beyond life expectancy. There may be differences in preference for 
conservative management vs. definitive therapy among PCa specialists.70 This bias may 
influence the extent to which clinicians consider life expectancy and could partially 
explain differences in overtreatment rates between radiotherapy and prostatectomy 
treated patients. Financial incentives to perform particular interventions may also play a 
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role.22 That county rates of prostatectomy from the Dartmouth Atlas predicted receipt of 
prostatectomy and radiotherapy also indicates that local biases towards particular 
interventions may influence treatment assignment.  
This study is subject to limitations that may impact the generalizability of findings. 
While SEER data have been validated and demonstrate adequate sensitivity and 
specificity for radical prostatectomy and radiotherapy,56,57 there remains potential for bias 
due to misclassification of treatment. However, treatment rates observed in this study 
were similar to rates from claims-based assessments of PCa treatment in older men 
over this same time period;24 thus misclassification was likely minimal. Additionally, 10-
year survival was calculated from date-of-diagnosis and thus approximated post-
treatment survival, as exact date-of-treatment was not available. However, differences 
between diagnosis and treatment dates were less than 1 year as SEER records primary 
treatments administered within 12 months of diagnosis.48 Finally, by opting not to predict 
10-year OCM risk at diagnosis, and instead reporting observed OCM rates, there is 
some potential for misclassification of overtreatment. For example, patients dying of 
unpredictable causes after definitive PCa treatment may not be fairly characterized as 
overtreated, as clinicians could not be expected to reasonably have anticipated some of 
these outcomes (e.g. subsequent development of another primary cancer). However, 
given that existing OCM prediction models are very limited in their ability to discriminate 
between individuals who die and those who survive,69 utilizing OCM predictions instead 
of observed rates may have potentially resulted in even greater rates of 
misclassification. Reporting observed 10-year OCM rates is an important component of 
understanding overtreatment and defining to what extent patients are prematurely dying 
prior to experiencing treatment benefit. 
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This study also has a number of strengths. The SEER-MHOS database allowed 
exploration of relationships with many validated health factors (e.g. comorbidity, physical 
health, and smoking) that have consistently been associated with OCM risk (Table 1.1). 
Thus it is unlikely that the lack of observed association between these factors and 
receipt of radiotherapy was due to poor specification of health status. Analyses were 
also adjusted for clinical factors that influence treatment assignment, summarized in the 
D’Amico risk score, and county-level variations in prostatectomy rates, both of which had 
important associations with treatment assignment. 
 
CONCLUSIONS  
While most older men with localized PCa undergo radiotherapy as a primary 
treatment for their disease, nearly a quarter of these men are overtreated, dying of non-
prostate causes within 10 years. In comparison, overtreatment with radical 
prostatectomy is less common, as worse overall health is associated with a reduced 
likelihood of receiving this treatment. Efforts are needed to improve patient selection for 
radiotherapy for PCa, particularly among older men with increasing comorbidity and 
limited physical health. 
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Figure 2.1: PCa treatment utilization by comorbidity burden and physical health 
Percentage of patients diagnosed from 2004-2009 with ≤cT3a prostate cancer managed with 
primary radical prostatectomy, primary radiotherapy, or managed conservatively by worse to 
better a) Charlson Comorbidity Index (CCI) score b) Physical Health (PCS) 
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Table 2.1: Patient characteristics at baseline by survival status at last follow-up 
 Total Prostate- Specific Death 
Other Cause 
Mortality Surviving p-value
α 
No. of patients (%) 2425 76 (3) 465 (19) 1884 (78) - 
Mean age at diagnosis 72.9 74.5 73.8 72.6 <0.001 
Race/ethnicity (%)      
   White 1879 (77) 57 (75) 371 (80) 1451 (77) 0.282 
   Black 290 (12) ~ 55 (12) 223 (12)  
   Hispanic/Asian/Pacific Islander or other 256 (11) ~ 39 (8) 210 (11)  
Charlson Comorbidity Index Score (%)     <0.001 
   0 1326 (54) 31 (40) 177 (38) 1118 (59)  
   1 586 (24) 18 (24) 130 (28) 438 (23)  
   ≥2 513 (21) 27 (35) 158 (34) 328 (17)  
Patient-Reported Physical Health      
   Mean PCS Score (IQR) 44 (36-53) 41 (32-53) 40 (30-51) 44 (38-53) <0.001 
Smoker at diagnosis (%) 301 (12) 18 (24) 86 (18) 197 (10) <0.001 
Tumor Grade     <0.001 
   Well to Moderately Differentiated 1630 (67) 30 (39) 338 (73) 1262 (67)  
   Poorly Differentiated or Unavailable* 795 (33) 46 (61) 127 (27) 622 (33)  
Tumor Clinical T-Stage     <0.001 
   cT1 1,193 (49) 20 (26) 227 (49) 939 (50)  
   cT2 819 (34) 34 (45) 136 (29) 649 (34)  
   cT1/T2 or T3a or Unavailable** 413 (17) 22 (29) 102 (22) 296 (16)  
Primary Prostate Cancer Management     <0.001 
   Conservative 794 (33) 46 (60) 197 (42) 551 (29)  
   Radical Prostatectomy 323 (13) ~ 28 (6) 294 (16)  
   Radiation Therapy 1308 (54) ~ 240 (52) 1039 (55)  
α Patient characteristics were compared among those dying of prostate cancer, other causes, and survivors using one-way 
analysis of variance tests and chi-squared tests as appropriate. 
~ exact n=,% not reportable per SEER-MHOS data use agreements as cell size <11 individuals for certain sub-categories 
*The small percentage of ungraded tumors were not reported individually in this table due to cell size reporting limitations and 
represented <3% of the total sample. 
**cT3a tumors contributed less than 2% to all categories; exact numbers were not reportable per SEER-MHOS data use 
agreements. Those without detailed cT-stage available (<3% of the sample) did not have regionalized/metastasized tumors, 
as confirmed by other SEER staging variables. 
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Table 2.2: Characteristics of patients considered in multinomial logistic model for treatment allocation 
 Total Primary Radical Prostatectomy 
Primary 
Radiotherapy 
Conservative 
Management p-value
α 
No. of patients (%) 1,316 172 (13) 597 (45) 547 (42) - 
Mean age at diagnosis  75.1 70.5 74.2 77.5 <0.001 
Race/ethnicity (%)     <0.001 
   White 872 (66) 108 (63) 375 (63)* 389 (71)  
   Black  153 (12) 19 (11) 75 (13) 59 (11)  
   Hispanic 119 (9) 17 (10) 61 (10) 41 (8)  
   Asian/Pacific Islander or other~ 172 (13) 28 (16) 86 (14)* 58 (10)  
Charlson Comorbidity Index Score 
(%)     <0.001 
   0 694 (53) 110 (64) 308 (52) 276 (50)  
   1 348 (26) 49 (28) 166 (28) 133 (24)  
   ≥2 572 (21) 13 (8) 123 (20) 138 (26)  
Patient Reported Physical Health      
   Mean PCS Score (IQR) 43 (35-52) 45 (38-54) 43 (36-52) 41 (32-51) <0.001 
Smoker at diagnosis (%) 152 (12) 18 (10) 76 (13) 58 (11) 0.47 
High school education or less (%) 696 (54) 82 (48) 316 (54) 298 (56) 0.21 
D’Amico Risk (%)     <0.001 
  Low 476 (36) 21 (12) 221 (37) 234 (43)  
  Intermediate 422 (32) 29 (17) 228 (38) 165 (30)  
  High 418 (31) 122 (71) 148 (25) 148 (27)  
Mean ratio of county RP rate to 
national RP rate 0.98 1.06 0.93 1.01 <0.001 
α Patient characteristics were compared among treatment groups using one-way analysis of variance tests and chi-squared tests as 
appropriate. 
~ SEER-MHOS data use agreements do not allow reporting of cell sizes <11 individuals, thus for table 1 Asian/Pacific Islander and other 
race categories were reported as a combined group, although analyzed separately in multivariate analyses. 
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Table 2.3: Adjusted multinomial logistic regression model predicting treatment allocation in 1268 patients with conservatively 
managed patients as the comparator group 
 Predictor Odds Ratio 95% Confidence Interval p-value 
R
ad
ic
al
 P
ro
st
at
ec
to
m
y 
Age at diagnosis (1 year increments) 0.71 0.67-0.75 <0.001 
Comorbidity Score (CCI) 0.61 0.46-0.80 <0.001 
Physical Health (PCS) 1 SD (10pts) lower 0.66 0.52-0.84 0.001 
Smoker at baseline 0.46 0.23-0.95 0.04 
D’Amico risk intermediate vs. low 3.00 1.55-5.79 0.001 
D’Amico risk high vs. low 19.70 10.91-35.57 <0.001 
Race vs. white    
   Black 1.07 0.53-2.18 0.84 
   Hispanic  1.88 0.88-4.05 0.15 
   Asian/ Pacific Islander 3.29 1.60-6.76 <0.001 
   Other cat. 0.50 0.12-2.00 0.33 
Education: high school or less 1.11 0.70-1.75 0.66 
Year of diagnosis 1.04 0.92-1.17 0.57 
Ratio of county radical prostatectomy rate to national rate 1.91 1.02-3.57 0.04 
R
ad
io
th
er
ap
y 
Age at diagnosis (1 year increments) 0.89 0.87-0.91 <0.001 
Comorbidity Score (CCI) 0.93 0.83-1.03 0.17 
Physical Health (PCS) 1 SD (10pts) lower 0.90 0.79-1.02 0.11 
Smoker at baseline 0.92 0.62-1.37 0.70 
D’Amico risk intermediate vs. low 1.87 1.39-2.53 <0.001 
D’Amico risk high vs. low 1.54 1.12-2.14 0.009 
Race vs. white      
   Black 1.04 0.69-1.57 0.83 
   Hispanic  1.54 0.97-2.45 0.07 
   Asian/ Pacific Islander 1.61 1.02-2.55 0.04 
   Other cat. 0.84 0.41-1.71 0.63 
Education: high school or less 0.92 0.89-1.03 0.56 
Year of diagnosis 0.96 0.89-1.03 0.21 
Ratio of county radical prostatectomy rate to national rate 0.55 0.37-0.83 0.004 
Bold typeface signifies factors previously associated with the risk of dying of non-PCa causes. In total, 168 men received radical prostatectomy, 
576 received radiotherapy, and 524 were conservatively managed.  
CCI: Charlson Comorbidity Index 
PCS: Physical Component Summary score 
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Table 2.4: Sensitivity analysis: Clustered multinomial logistic model predicting treatment allocation, clustered by county, with 
conservatively managed patients as the comparator group 
 
  
 Predictor Odds Ratio 95% Confidence Interval p-value 
R
ad
ic
al
 P
ro
st
at
ec
to
m
y 
Age at diagnosis (1 year increments) 0.70 0.66-0.74 <0.001 
Comorbidity Score (CCI) 0.60 0.46-0.79 <0.001 
Physical Health (PCS) 1 SD (10pts) lower 0.67 0.52-0.85 0.001 
Smoker at baseline 0.47 0.22-0.97 0.04 
D’Amico risk intermediate vs. low 2.92 1.51-5.66 0.002 
D’Amico risk high vs. low 20.39 11.21-37.08 <0.001 
Race/ethnicity vs. white    
   Black 1.03 0.50-2.14 0.93 
   Hispanic  1.69 0.77-3.70 0.19 
   Asian/ Pacific Islander 2.42 1.11-5.29 0.03 
   Other cat. 0.47 0.12-1.87 0.28 
Education: high school or less 1.08 0.68-1.71 0.76 
Year of diagnosis 1.04 0.93-1.17 0.51 
Ratio of county radical prostatectomy rate to national rate 1.78 0.83-3.80 0.14 
R
ad
io
th
er
ap
y 
Age at diagnosis (1 year increments) 0.88 0.86-0.91 <0.001 
Comorbidity Score (CCI) 0.92 0.82-1.03 0.16 
Physical Health (PCS) 1 SD (10pts) lower 0.91 0.80-1.03 0.14 
Smoker at baseline 0.94 0.62-1.41 0.75 
D’Amico risk intermediate vs. low 1.81 1.33-2.47 <0.001 
D’Amico risk high vs. low 1.60 1.14-2.24 0.007 
Race/ethnicity vs. white       
   Black 1.01 0.65-1.57 0.95 
   Hispanic  1.38 0.85-2.26 0.20 
   Asian/ Pacific Islander 1.17 0.66-2.06 0.60 
   Other cat. 0.75 0.36-1.58 0.45 
Education: high school or less 0.90 0.68-1.19 0.46 
Year of diagnosis 0.96 0.92-1.10 0.15 
Ratio of county radical prostatectomy rate to national rate 0.53 0.30-0.96 0.04 
Bold typeface signifies factors previously associated with the risk of dying of non-PCa causes. In total, 168 men received radical prostatectomy, 
576 received radiotherapy, and 524 were conservatively managed. 
CCI: Charlson Comorbidity Index 
PCS: Physical Component Summary score 
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Table 2.5: Sensitivity analysis: low-intermediate D’Amico risk patients only: Multinomial logistic model predicting treatment 
allocation, in 858 patients, with conservatively managed patients as the comparator group 
 
 
Predictor Odds Ratio 95% Confidence Interval p-value 
R
ad
ic
al
 P
ro
st
at
ec
to
m
y 
Age at diagnosis (1 year increments) 0.77 0.72-0.83 <0.001 
Comorbidity Score (CCI) 0.66 0.44-0.98 0.04 
Physical Health (PCS) 1 SD (10pts) lower 0.76 0.54-1.07 0.11 
Smoker at baseline 0.26 0.06-1.19 0.08 
D’Amico risk intermediate vs. low 2.63 1.51-5.66 0.003 
Race/ethnicity vs. white    
   Black 0.76 0.24-2.44 0.65 
   Hispanic  1.72 0.62-4.79 0.30 
   Asian/ Pacific Islander 3.22 1.18-8.81 0.02 
   Other cat. - - - 
Education: high school or less 0.72 0.37-1.39 0.33 
Year of diagnosis 0.93 0.78-1.11 0.40 
Ratio of county radical prostatectomy rate to national rate 1.52 0.60-3.86 0.38 
R
ad
io
th
er
ap
y 
Age at diagnosis (1 year increments) 0.89 0.86-0.92 <0.001 
Comorbidity Score (CCI) 0.97 0.85-1.11 0.69 
Physical Health (PCS) 1 SD (10pts) lower 0.85 0.74-0.99 0.04 
Smoker at baseline 0.92 0.58-1.47 0.73 
D’Amico risk intermediate vs. low 1.85 1.37-2.51 <0.001 
Race/ethnicity vs. white       
   Black 1.01 0.63-1.62 0.97 
   Hispanic  1.48 0.87-2.51 0.15 
   Asian/ Pacific Islander 1.80 1.04-3.14 0.04 
   Other cat. 0.88 0.38-2.06 0.78 
Education: high school or less 0.84 0.62-1.15 0.28 
Year of diagnosis 0.93 0.86-1.01 0.11 
Ratio of county radical prostatectomy rate to national rate 0.56 0.35-0.90 0.02 
Bold typeface signifies factors previously associated with the risk of dying of non-PCa causes. In total, 50 men received radical prostatectomy, 
449 received radiotherapy, and 399 were conservatively managed. 
Note: This analysis was limited by sample size, with far fewer than 10 outcomes per covariate in the radical prostatectomy group.  
CCI: Charlson Comorbidity Index 
PCS: Physical Component Summary score 
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Supplement 2.A: Sensitivity Analysis: Re-estimation of 10-year cumulative incidence of 
other cause mortality by treatment type including patients >80 years of age at diagnosis 
 Limiting the population in the main analysis of 10-year OCM rates by PCa treatment type to 
patients <80 years of age at PCa diagnosis may have biased the estimates of 10-year OCM downward, 
thus, a sensitivity analysis was performed. Cumulative incidence distributions of 10-year non-PCa death by 
treatment type were re-estimated including patients >80 years of age in the analysis to assess potential 
underestimation of OCM rates by excluding these patients from the main analysis.  
The sample grew from 2,425 individuals in the main analysis to 2,931 men, by including those men 
over 80 years of age at PCa diagnosis. Mean age increased to 75 from 74. Recalculated cumulative 
incidence of 10-year OCM among radical prostatectomy, radiotherapy, and conservatively managed patients 
was 12%, 24%, and 38%, respectively. Thus, the estimates of 10-year cumulative incidence of OCM largely 
did not change for patients who underwent radical prostatectomy or radiotherapy. The estimate for 
conservatively managed men did, however, increase by 7%. The distributions of treatment assignment 
between the main analysis cohort and the sensitivity analysis cohort are detailed in Table 2A1. The vast 
majority of those over 80 years of age at diagnosis were conservatively managed (75%), with almost no 
patients receiving radical prostatectomy.   
 
Table 2.A.1: Number of patients by treatment type in the main analysis cohort and the 
sensitivity analysis 
Treatment Modality 
Main Analysis Cohort  
(2,425 patients) 
Number of Patients: 
Sensitivity Analysis Cohort 
(2,931 patients) 
Number of Patients: 
Definitive Treatment:  
Radical Prostatectomy or 
Radiotherapy* 
1631 (67%) 1757 (60%) 
Conservative Management 794 (33%) 1174 (40%) 
*Due to SEER-MHOS data agreements the exact number of patients undergoing radical prostatectomy in 
the sensitivity analysis cohort cannot be reported, as the number of patients added to the main analysis 
cohort was <11, below the minimum reportable cell size. Thus, the number of radical prostatectomy or 
radiotherapy treated patients is reported as one category. The vast majority of patients added (75%) were 
conservatively managed.  
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CHAPTER III: EVALUATION OF 10-YEAR OTHER CAUSE MORTALITY RISK 
ESTIMATES FOR MEN WITH PROSTATE CANCER 
 
ABSTRACT 
Objective: To evaluate the performance of 10-year mortality risk estimates from the 
Social Security life tables, recommended by clinical guidelines for life-expectancy 
estimation in men with prostate cancer (PCa), as compared to newer tools for estimating 
other cause mortality (OCM) risk. 
Methods: 2,931 men newly diagnosed with clinical stage T1a-T3a PCa from 1998-2009 
were identified from the linked Surveillance Epidemiology and End Results - Medicare 
Health Outcomes Survey (SEER-MHOS) database with a median follow-up of 7.7 years. 
Predicted 10-year mortality risk from Social Security life tables, from an OCM risk 
estimation nomogram, and an OCM risk estimation table were compared to observed 
10-year all-cause mortality and observed 10-year OCM rates across quintiles of patients 
with increasing predicted risk, with quintiles defined separately for each tool. Observed 
all-cause mortality rates were determined with Kaplan-Meier methods; observed OCM 
rates with cumulative incidence distributions for 10-year OCM. The prediction models’ 
ability to discriminate between those who died and those who did not was evaluated with 
Harrell’s c-index (range: 0.5-1.0). 
Results: The Social Security method predicted 26% 10-year all-cause mortality among 
the lowest risk quintile of patients (vs. observed rate: 20%), and predicted 58% mortality 
for the highest risk quintile (vs. observed rate: 42%). Predicted OCM rates from the two 
OCM risk estimation tools were closer to observed rates. Among the lowest risk quintiles 
of patients the predicted OCM rates ranged from 14-22%, while observed OCM rates 
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were 14-15%. Among the highest risk quintiles of patients predicted OCM rates ranged 
from 46-57%, while observed OCM rates were 38-39%. Using Social Security estimates, 
discrimination between those who died and those who did not was poor (c-index: 0.59). 
OCM specific tools provided slightly improved discrimination (c-index: 0.64 for both 
tools).  
Conclusions: OCM risk estimation tools evaluated in this study provided more accurate 
estimates of 10-year mortality rates and more optimally discriminated between 
individuals dying and surviving during this time period than Social Security life table 
estimates.  However, these tools remain limited in their ability to distinguish between 
individuals who will die versus those who will not; thus they may have limited clinical 
utility. 
 
INTRODUCTION 
 Clinical care guidelines consistently recommend that definitive prostate cancer 
(PCa) therapies be reserved for patients with at least a 10-year life expectancy.7,9,53 For 
the 100,000 men annually diagnosed in the U.S. with low-risk prostate cancers, 
regardless of treatment, the probability of dying from PCa within 10 years of diagnosis is 
less than 5%.10,11 In contrast, the competing risk of dying of other non-PCa causes within 
10 years of diagnosis can range from as little as 6% for the youngest and healthiest men 
to over 90% among older men with high comorbidity burden.10,12–15 While accurately 
predicting this highly variable non-prostate mortality risk is important to life-expectancy 
estimation, less than one quarter of prostate cancer specialists routinely incorporate this 
into practice.16  
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 One potential explanation for the limited adoption of life expectancy evaluation is 
the dearth of validated and endorsed evaluation methods.17,28 The National 
Comprehensive Cancer Network guidelines have recommended utilization of the Social 
Security life tables for evaluating overall life expectancy for men with prostate cancer.9,25 
These life tables provide a simple age-based assessment of predicted life expectancy 
based on data from males in the general U.S. population. However, ideally, clinicians 
should incorporate more individualized assessments of their patients’ health status in 
their estimations of life expectancy. Clinicians should also be able to determine the risk 
of other cause mortality (OCM) separately from PCa specific mortality (PCSM) risk.26 To 
address these needs tools have been developed for clinical use to predict the risk of 
OCM in patients with PCa, incorporating assessments of patients’ comorbidities (Table 
3.1).7,10,12,26,27 However, whether these risk estimation tools provide clinically useful 
determinations of life expectancy in men with localized PCa has yet to be determined. 
 To be useful in the clinic, risk estimation tools must be able to correctly 
discriminate between individual patients who will experience the predicted event and 
those who will not. These tools must also closely predict the observed rate of events 
across groups of patients with increasing risk.  The present study evaluates whether two 
newer OCM risk estimation tools, specifically developed in populations of men with 
localized PCa, can substantially improve the accuracy of risk estimates and better 
discriminate between patients who die of OCM and those who do not, as compared to 
the existing Social Security life tables.  
 
 
 
33 
Chapter III 
METHODS 
Predicted 10-year mortality risk estimates were compared from three different 
tools: (1) Social Security all-cause mortality estimates for men in the U.S. general 
population,71 (2) a nomogram for predicting OCM risk developed in the Cancer of the 
Prostate Strategic Urologic Endeavor (CaPSURE) database,26 (3) and a life table for 
OCM risk estimation developed from the Prostate Cancer Outcomes Study (PCOS)10 
(Table 3.1). The CaPSURE nomogram and PCOS life tables were selected for 
evaluation as they represent two main approaches to risk estimation (nomograms and 
life tables) and could be reasonably evaluated with the limitations of the data available 
for this study. Two other available tools for OCM risk estimation were not evaluable 
either due to limitations in reproducing predictors or because the tool only became 
available as this dissertation was finalized (Table 3.1).  
Data Source 
This study utilized the Surveillance, Epidemiology, and End Results (SEER) - 
Medicare Health Outcomes Survey (MHOS) linked database. The SEER-MHOS 
database provides data on 19,727 men with PCa with follow-up survival data available 
through February 2013. Patients’ sociodemographic, tumor, and treatment 
characteristics are populated from the National Cancer Institute’s SEER cancer registry. 
The SEER program collects comprehensive cancer data representative of 26% of the 
U.S. population through regional registries across the U.S.54 Self-reported comorbidity 
and health behavior data were collected through the Centers for Medicare & Medicaid 
Services’ (CMS) MHOS survey. Beginning in 1998 CMS annually surveyed Medicare 
managed care plan participants to monitor health outcomes, with response rates ranging 
from 64-72%.48 Medicare managed care enrollees account for roughly 19% of all 
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Medicare beneficiaries. From 1998-2011 over 1.6 million enrollees completed surveys 
for the MHOS.55 Details of the SEER-MHOS linkage and prospective data collection 
methods have been previously described.48 
Study Population 
Patients were selected if newly diagnosed with PCa between January 1, 1998 
and December 31, 2009, and if they completed an MHOS survey within the 3 years 
preceding their PCa diagnosis. Exclusion criteria included diagnosis of PCa on autopsy 
or death certificate or if diagnosed with regionalized or metastasized tumors (stage > 
cT3a). For the primary analysis the sample was restricted to patients age <80 at PCa 
diagnosis as the decision to undergo definitive treatment is most relevant in this 
population. Secondary analyses included all patients age 66 and older at PCa diagnosis 
in order to assess the performance of risk estimates in a population that included the 
oldest patients. 
Data Collected 
Age, demographic, comorbidity, and treatment variables were selected to 
approximate variables from previously developed tools for OCM risk estimation.10,26 Age 
at diagnosis was determined from the SEER registry. Comorbidity was assessed with 
two methods. A “CaPSURE comorbidity count” variable was generated utilizing a count 
of self-reported conditions in MHOS that overlap with disease categories used to 
generate the comorbidity count for the nomogram: hypertension, heart disease, stroke, 
diabetes, chronic obstructive pulmonary disease [COPD], cancer.26 A Charlson 
Comorbidity Index (CCI) score was also generated utilizing Charlson weights for 8 self-
reported conditions in MHOS (myocardial infarction, congestive heart failure, stroke, 
COPD, diabetes, inflammatory bowel disease, paralysis, other cancer), which overlap 
35 
Chapter III 
with conditions in the CCI.34 Full details on this study’s adaptations to comorbidity inputs 
for the CaPSURE and PCOS tools are available in Supplement 3.A. Race, reported in 
SEER, was categorized as white, black, Hispanic, Asian/Pacific Islander, and other. 
SEER collects treatment information on patients’ first course of therapy, or primary 
surgical and radiotherapies. We considered patients who underwent radical 
prostatectomy as having received definitive surgical therapy and classified patients 
undergoing brachytherapy, external beam radiation, or a combination of the two as 
having received definitive radiotherapy. 
Survival and Mortality Outcomes 
Survival and detailed cause of death were ascertained through the SEER portion 
of the linked dataset. Patient deaths were classified as due to PCSM versus OCM using 
the SEER cause of death recode variable (codpub). Survival was calculated as the 
difference between the date of diagnosis and the date of death, or last SEER follow-up 
date for censored patients. Patients not experiencing OCM or PCSM within 10 years of 
PCa diagnosis were censored at 10 years  if followed ≥10 years after diagnosis, or at 
time of last SEER follow-up if followed <10 years. 
Assignment of OCM Risk Estimates 
Using the Social Security life tables annual risk of mortality, reported for the 
general male U.S. population,71 the risk of dying within the next 10 years of all causes 
was computed and assigned to each patient with age rounded to integer values. OCM 
risk estimates were also derived for all patients in the database using the CaPSURE and 
PCOS tools. Inputs for the CaPSURE and PCOS tools were approximated closely, but 
were adapted as described below when limited by the available SEER-MHOS data.  
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The CaPSURE nomogram OCM risk scores were derived based on age, 
“CaPSURE comorbidity count,” radiotherapy or conservative management vs. radical 
prostatectomy, and race black vs. white or other.26 Because data on androgen 
deprivation therapy were not available in SEER-MHOS, nomogram risk scores were 
computed without this input. While the CaPSURE tool was originally developed with data 
from definitively treated patients, the developers have recommended the nomogram for 
pretreatment OCM risk estimation in allcomers.26 Thus, risk scores were also generated 
for conservatively managed patients. Conservatively managed patients were assigned 
the same points as radiotherapy treated patients, as conservatively managed patients 
have a higher risk of OCM than radical prostatectomy treated patients (as demonstrated 
in Chapter II), and this was thought to mirror how a clinician may apply the risk calculator 
to patients in a pre-treatment clinical setting. PCOS life table risk scores were assigned 
to patients based on comorbidity count from approximated CCI scores and patients’ age 
at diagnosis.10 Supplement 3.A describes differences between original CaPSURE and 
PCOS model comorbidity inputs and adaptations made to model inputs in more 
extensive detail.   
Statistical Analysis 
Predictive accuracy was evaluated by dividing the population into predicted risk 
groups and assessing the prevalence of observed mortality within each risk group. Risk 
scores were derived from each prediction method and divided into quintiles. Patients 
were assigned to quintiles of risk, defined separately for each tool.  Kaplan-Meier 
methods were used to estimate observed all-cause mortality for patients in each quintile 
of Social Security predicted mortality risk. To estimate observed OCM in the study 
population, cumulative incidence of 10-year OCM was computed utilizing modified 
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Kaplan-Meier methods that account for the competing risk of dying of PCa.64 Observed 
cumulative incidence of OCM was compared to predicted risk for each of the risk 
estimation methods at each risk quintile. The percentage of subjects assigned a risk 
score >0.5 was noted for each method as this threshold is thought to correspond to a 
life-expectancy <10 years.12 The sensitivity, specificity, positive and negative predictive 
values of having >50% predicted risk were calculated for each method. The “gold-
standard” comparison for these assessments was death or survival during 10 years of 
follow-up after PCa diagnosis. 
Discrimination with survival data was measured with Harrell’s c-index 
(concordance-index).64 This index evaluates whether pairs of patients in the dataset 
have the relative outcome that would be expected given the risk score assigned from the 
model. A pair is considered concordant if a patient with higher predicted risk experiences 
the event before a patient with a lower risk score. The pair is considered discordant if a 
patient with a lower risk score experiences the event sooner than someone with a higher 
risk score. The index evaluates all pairs of patients in the data where at least one 
individual experienced the event. The index is calculated as the ratio of evaluable 
concordant to discordant pairs with a range of 0.5 to 1.0. A model that performs no 
better than a random prediction will achieve a score of 0.5 while a model that perfectly 
discriminates between all comparable pairs of individuals in the data set is rated 1.0. C-
index values >0.7 are considered of modest clinical utility, while values >0.8 are 
considered genuinely clinically useful; below these thresholds models are considered of 
limited to poor clinical value.72,73 
 To evaluate whether predictors reported in the CaPSURE OCM risk estimation 
nomogram remained associated with OCM in SEER-MHOS data and had similar sized 
38 
Chapter III 
effects on mortality risk, Fine and Gray competing risks regression for OCM risk was 
fitted with the re-approximated predictors from the nomogram, with PCa death as the 
competing risk.74 This analysis was not performed for the PCOS tool predictors as the 
original publication did not report details of the regression model results, limiting the 
ability to make comparisons.10 The complete case method was used. The cumulative 
incidence analyses of OCM were conducted with SAS v9.3 (SAS Institute, Cary, NC), 
while all other analyses utilized Stata IC 12 software (College Station, TX).   
 
RESULTS 
 Of the 19,727 patients with PCa linked between SEER and MHOS databases, 
2,931 were newly diagnosed with localized, clinical stage T1a-T3a PCa between 
January 1, 1998 and December 31, 2009 and completed an MHOS survey within 3 
years preceding their PCa diagnosis. The primary analysis included 2,425 patients age 
80 or younger at PCa diagnosis.  Median follow-up was 7.7 years, over which 24.3% of 
eligible men died of OCM and 3.7% of PCa. Complete sample characteristics for the 
primary analysis cohort are reported in Table 3.2. 
Social Security All-Cause Mortality Predictions 
The Social Security risk tables over-predicted all-cause mortality in the study 
population (Table 3.3). Using the Social Security tables, patients in the lowest risk 
quintile had a predicted 26% all-cause mortality rate, while the observed all-cause 
mortality rate in the SEER-MHOS population was 20% (95% CI 17-25%). Similarly, 
patients in the highest risk quintile had a predicted 58% all-cause mortality rate, but an 
observed rate of only 42% (95% CI: 37-48%) mortality as estimated with Kaplan-Meier 
methods. Harrell’s c-index was 0.59 for the Social Security all-cause mortality 
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predictions, suggesting poor discrimination between individuals who died or survived 
over 10 years of follow-up.  In contrast to all-cause mortality, OCM rates were 
consistently 3-7% lower across all quintiles of predicted risk. This difference may be due 
to the low additional risk of PCSM that may be captured in the all-cause mortality risk 
estimate but is not accounted for when estimating only OCM risk (Table 3.3).  
Overall, 25% of the sample received a Social Security life table risk score of 50% 
or higher, suggestive of a <10 year life expectancy. This >50% threshold resulted in a 
35% sensitivity for all-cause mortality observed during the available follow-up in the 
SEER-MHOS population; the positive predictive value of the life tables compared to 
observed deaths was 31%, and the negative predictive value was 81% (Table 3.3). 
Other Cause Mortality Prediction Tools 
 Tools specifically developed to measure OCM more often provided accurate 
estimates of OCM rates. However, both the CaPSURE nomogram and PCOS life table 
OCM risk estimation tools still somewhat over predicted risk compared to the observed 
OCM rates obtained from the SEER-MHOS cohort (Table 3.3). For patients in the lowest 
CaPSURE and PCOS risk quintiles the tools predicted average OCM risk from 14-22% 
while the OCM rate for patients in these lowest risk quintiles was only 14-15%. For 
patients in the highest CaPSURE and PCOS risk quintiles the tools predicted 46-57% 
OCM risk; in comparison, the rate of OCM in the highest quintile groups only ranged 
from 38-39%. Overall, the PCOS life table predictions were closest to observed OCM 
rates across the greatest number of risk groups in the SEER-MHOS study population, 
with well-calibrated estimates for quintile 1 and 4, but slightly overestimated OCM in the 
other quintiles (Table 3.3). For the highest risk quintile of patients, the CaPSURE 
nomogram provided the most accurate predictions. Both the CaPSURE nomogram and 
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PCOS life tables improved upon Social Security estimates in terms of discriminating 
between those who died and those who did not. Risk estimates from both prediction 
tools achieved a Harrell’s c-index of 0.64.  
Utilizing a 50% OCM risk threshold for determining <10 year life expectancy was 
insufficient as a potential threshold for clinical action; positive predictive value for OCM 
was highest at 37% for the CaPSURE nomogram, and lowest for the PCOS life tables at 
30%. Sensitivity for OCM was poor for both methods; the CaPSURE nomogram had a 
sensitivity of 8% with a specificity of 97% while the PCOS life tables were only 
marginally better with a 13% sensitivity and 93% specificity.   
Secondary Analyses: Predictions for Older Patients 66+  
There were 2,854 patients age 66 and older included in the secondary analyses. 
Population characteristics for the secondary analysis cohort are detailed in Table 3.4. 
The performance of the OCM estimation tools generally improved in the older 
population. 
Social Security life tables continued to overestimate all-cause mortality in this 
population across all risk quintiles (Table 3.5). The lowest risk quintile of patients had a 
predicted 29% all-cause mortality rate, while observed all-cause mortality was 19% (95% 
CI: 16-22%), and patients in the highest risk quintile had an average 77% predicted all-
cause mortality rate, but only experienced 59% (95% CI: 53-65%) mortality as estimated 
with Kaplan-Meier methods. The risk of dying of all-causes vs. OCM diverged even more 
in this older cohort (Table 3.5). Harrell’s c-index improved to 0.66 for the Social Security 
all-cause mortality predictions, suggesting improved discrimination among older patients. 
A risk score of 50% or higher, suggestive of a <10 year life expectancy, was assigned to 
39% of the population. This threshold provided 56% sensitivity for all-cause deaths 
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observed during the available follow-up, had a positive predictive value of 39%, and 
negative predictive value of 81% (Table 3.5). 
The CaPSURE and PCOS OCM prediction tools also continued to over predict 
OCM risk, although the extent to which overestimation occurred diminished (Table 3.5). 
In this cohort of older men, the CaPSURE nomogram had markedly improved 
performance among the highest OCM risk group where the model and observed 
estimates were very similar (60% predicted vs. 58% observed). PCOS life table 
estimates overlapped with observed OCM rates for more quintiles (1, 3 and 4) and the 
degree of overestimation diminished for quintile 5. Discrimination (c-index) improved for 
the two tools ranging from 0.65-0.68 (Table 3.5). A risk score of 50% continued to be a 
poor threshold for OCM prediction, with sensitivity ranging from 15-27%. Table 3.5 
details full performance of this threshold. 
Re-estimation of CaPSURE model coefficients 
For the CaPSURE nomogram, refitting of a Fine and Gray competing risks 
regression model in the primary analysis cohort (patients <80 years of age at diagnosis) 
revealed very similar associations between the key predictors (age and comorbidity 
count) and the risk of OCM (Table 3.6). Radiotherapy treatment vs. radical 
prostatectomy was associated with a greater likelihood of OCM in this cohort (HR: 1.64, 
95% CI: 1.08-2.46 vs. previously reported HR: 1.26, 95% CI 1.07-1.49). However, 
African American race was no longer significantly associated with OCM in this cohort.  
  
DISCUSSION 
 This study presents an evaluation of currently available methods for estimating 
OCM risk in a cohort of older American men with localized PCa. The objective of this 
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work was to determine the performance of Social Security life table mortality risk 
estimates, recommended for life expectancy estimation, as compared to available OCM 
risk estimation methods. Accurate and reliable prediction of life expectancy, which is 
primarily defined by OCM risk, is a necessary prerequisite for improving treatment 
decision-making for PCa and reducing overtreatment.12,14,15 As applied to this data 
source, the mortality estimates derived from the Social Security life tables overestimated 
all-cause mortality and OCM risk and performed poorly in discriminating between 
individuals who survived and died, well below thresholds for making reliable clinical 
distinctions at the individual patient level.72 OCM risk estimation tools derived using data 
from CaPSURE and PCOS improved upon Social Security estimates, with less 
overestimation of OCM risk and better discrimination between those who died and those 
who did not. However, overall discrimination of both CaPSURE and PCOS OCM risk 
estimation tools remained limited with c-index values of 0.64 among patients less than 
80 years of age at diagnosis, suggesting these tools may have suboptimal performance 
for individualized clinical decision-making. Future OCM risk estimation tools may benefit 
from incorporation of additional predictors which help to more accurately discriminate 
between higher and lower risk patients. 
The Social Security life tables, which past guidelines have recommended 
clinicians rely upon for determining life expectancy7 and which rely only on age to derive 
predictions, appear to provide the poorest risk classification of patients among available 
methods as well as some of the least accurate predictions of all-cause and true OCM 
risk in this cohort of older Americans. The PCOS life tables and CaPSURE nomogram, 
which additionally account for self-reported comorbidity, improved upon the performance 
of the Social Security life table estimates and provided the most optimal balance of 
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better estimating the true rate of OCM as well as discriminating between individuals who 
survived and died. However, further improvements to all of the models assessed may be 
required before they can be reliably applied to individual patients in the clinic. 
Ultimately, these tools are intended to aid in making better treatment decisions, 
which requires defining thresholds for changing clinical action. If these three tools were 
relied upon for making clinical treatment decisions, utilizing a recommended cut point of 
50% OCM risk to predict <10 years life expectancy,12 depending on which tool was 
utilized, a substantially different proportion of patients would be recommended for 
conservative treatment. Social Security life tables would result in almost 25% to 39% of 
patients being conservatively managed while other methods would lead to just fewer 
than 4% being conservatively managed. This crude cut point-based approach for 
decision-making may not be an optimal mechanism for utilizing these risk estimation 
tools. The 50% threshold resulted in poor sensitivity for detecting deaths. While the 
CaPSURE nomogram and PCOS risk tables provided the best estimates of the true rate 
of OCM, utilizing a threshold of 50% risk as a predictor of <10 year life expectancy only 
detected 4% to 8% of the observed deaths. The vast majority of the observed OCM 
deaths occurred among patients with a <50% predicted risk of OCM. Perhaps a more 
useful way to utilize such tools would be to more carefully consider conservative 
management among the highest 2 or 3 risk quintiles of patients who account for the 
majority of the observed OCM deaths during follow-up.  
 Re-estimation of the CaPSURE nomogram regression model in the SEER-
MHOS population revealed that the associations for age and comorbidity- the two most 
important predictors in the model- were closely reproduced. This may suggest that some 
of the differences observed in OCM risk across populations may be attributable to 
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differences in the baseline risk of OCM. Thus, providing clinicians with mechanisms for 
recalibrating risk estimates to better fit mortality rates in their populations may be one 
solution to improving the accuracy of these tools. The differences in risk estimates may 
also be attributable to the varied prevalence of comorbidities between the cohorts in 
addition to unmeasured confounding.  
This study has several limitations. While this work provides important insights 
into the performance of available mortality risk estimation tools, poor performance of any 
particular tool may partly be attributed to limitations in approximating model inputs. While 
efforts were made to approximate comorbidity assessments from the published tools, 
modifications were required as described in Supplement 3.A. The approach presented 
here should still be informative to clinicians who may similarly attempt to approximate 
model inputs in a real-world setting, and may provide a cautionary example highlighting 
the importance of reproducing model inputs as closely as possible. It should also be 
noted that life tables required assigning the same risk scores to large groups of patients, 
limiting the opportunity for the PCOS tool to discriminate between individuals’ risk. Were 
a continuous PCOS prediction model available, discrimination would likely be improved 
over what is reported in this manuscript using life table OCM risk estimates. There is 
additionally some potential for misclassification of death, the outcome variable.  
However, prior work has shown the SEER mechanism for accounting for and attributing 
cause-specific death to be reliable and valid.75  
  Future OCM risk estimation tools should consider incorporating easily 
obtainable, well-defined predictors that clinicians can easily reproduce to improve the 
discrimination between individuals who die of OCM and those who do not. The addition 
of comorbidity to age improved discrimination, as evidenced by all tools providing 
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improved risk classification over Social Security life table risk estimates. At best, the 
current models have limited predictive value in terms of classifying patients from highest 
to lowest risk. Prior work has suggested that patient-reported measures of functioning as 
well as sociodemographic variables may have value in predicting OCM.33 Improving risk 
classification of prediction tools via parsimonious addition of high value predictors could 
add to their clinical utility. Additionally, incorporation of treatment variables complicates 
application of OCM risk estimation tools as a pre-treatment decision aid, as was 
highlighted when applying the CaPSURE nomogram risk estimates to this population. 
Limiting risk estimation tools to pre-treatment variables would also promote their utility in 
decision-making. Finally, the accuracy of the estimates from each of the tools was 
limited in the SEER-MHOS population, likely because the death rates in the SEER-
MHOS database were relatively low. Thus providing a mechanism for clinicians to 
recalibrate risk estimation tools to death rates observed in their populations would also 
assist in promoting the accuracy of estimates from these tools. 
 
CONCLUSIONS 
The evaluated OCM risk estimation tools provide more accurate classification of 
patient mortality risk and absolute estimates of this risk than Social Security life tables.  
However, the tools remain limited in their ability to distinguish between individuals likely 
to die of OCM versus those who will not, which may limit the clinical utility of these tools.  
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Table 3.1: Published other cause mortality risk estimation tools assessed in Chapter III vs. recommended Social Security life 
table mortality estimates 
 Publication First 
Author 
Database 
Utilized 
Type of Risk 
Estimation Tool 
Outcome 
Estimated               Predictors 
A
ss
es
se
d 
in
 C
ur
re
nt
 S
tu
dy
 
Social Security 
Administration71  
U.S. General 
Population 
Males 
Life table (categories 
from table matrix) 
10-year all-cause 
mortality  Age at diagnosis 
Kutikov26 CaPSURE 
Nomogram 
(continuous 
predictions of risk) 
10-year OCM 
 Age at diagnosis 
 Comorbidity count 
 Treatment with radiotherapy vs. radical 
prostatectomy 
 Receipt of androgen deprivation therapy* 
 Race (black vs. white) 
Daskivich10 PCOS Life table (categories from table matrix) 10-year OCM 
 Age at diagnosis  
 Self-reported list of comorbid conditions 
(Supplement 3.A) 
N
ot
 A
ss
es
se
d 
In
 
C
ur
re
nt
 S
tu
dy
±  Daskivich12 SEER-Medicare 
Life table (categories 
from table matrix) 10-year OCM 
 Age at diagnosis  
 Claims-based Charlson Comorbidity 
Index 
Hoffman27 PCOS 
Nomogram 
(continuous 
predictions of risk) 
10-year OCM 
 Age at diagnosis 
 Race /Ethnicity (Hispanic  vs. white vs. 
black) 
 Self-rated health (excellent/very 
good/good/fair-poor) 
*Predictor unavailable in SEER-Medicare database but has minor contribution to overall risk score 
± After consultation with Dr. Daskivich et al., the SEER-Medicare life table estimates were not assessed in the current study as the claims-
based specification of comorbidity could not be replicated well in the SEER-MHOS database. The Hoffman nomogram was published after 
the analyses and writing for Chapter III were complete and thus was not available for assessment during the course of this study. Its 
performance was instead briefly evaluated in Chapter IV of this dissertation. The Walz and Tewari nomograms for all-cause mortality 
prediction (listed in Table 1.1) were not evaluated in this study as they do not provide specific assessments of OCM risk which the field has 
moved toward for more accurate distinct estimates of OCM.  
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Table 3.2: Patient characteristics: primary analysis sample 
 Total Prostate-Specific Death 
Other Cause 
Mortality Surviving 
No. of patients (%) 2425 76 (3) 465 (19) 1884 (78) 
Mean age at diagnosis 72.9 74.5 73.8 72.6 
Race/ethnicity (%)     
   White 1879 (77) 57 (75) 371 (80) 1451 (77) 
   Black 290 (12) ~ 55 (12) 223 (12) 
   Hispanic/Asian/Pacific Islander or other 256 (11) ~ 39 (8) 210 (11) 
CaPSURE Comorbidity Count (%)     
   0 476 (36) 16 (21) 81 (17) 516 (27) 
   1 422 (32) 14 (18) 130 (28) 642 (34) 
   ≥2 418 (31) 46 (60) 254 (54) 726 (39) 
Charlson Comorbidity Index Score (%)     
   0 1326 (54) 31 (40) 177 (38) 1118 (59) 
   1 586 (24) 18 (24) 130 (28) 438 (23) 
   ≥2 513 (21) 27 (35) 158 (34) 328 (17) 
PCa Management     
   Conservative 794 (33) 46 (60) 197 (42) 551 (29) 
   Radical Prostatectomy 323 (13) ~ 28 (6) 294 (16) 
   Radiation Therapy 1308 (54) ~ 240 (52) 1039 (55) 
~ exact n=,% not reportable per SEER-MHOS data use agreements as cell size <11 individuals for certain sub-categories 
Further details on patient tumor characteristics for the identical sample can be found in Table 2.2 (Chapter II) 
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Table 3.3: Comparison of predicted to observed percent deaths for three risk estimation methods: Social Security life tables, 
CaPSURE and PCOS tools in men age ≤ 80 
 
 
 
 
 
  
Risk Estimation Tool Risk  Type 
Percent 10-year Mortality by QuintileΔ of Risk (95% CI) Harrell’s  
c-index 
Performance 
Measures 
Quintile 1  Quintile 2 Quintile 3 Quintile 4 Quintile 5 
Social Security  
Life Table  
Predicted 26 33 40 49 58 
0.59 
>50% risk: 25% 
**PPV: 31% Se: 35% 
NPV: 81% Sp: 78% 
Observed All-
Cause Mortalityα 
20 (17-25) 24 (20-29) 25 (21-29) 33 (28-39) 42 (37-48) 
Observed OCM± 18 (15-22) 20 (16-25) 22 (18-26) 29 (24-34) 35 (29-40) 
CaPSURE Nomogram  
Predicted 22 28 33 38 46 
0.64 
>50% risk: 4% 
PPV: 37% Se: 8% 
NPV: 81% Sp: 97% Observed OCM
± 14 (11-18) 21 (17-25) 23 (18-29) 30 (26-35) 39 (33-45) 
PCOS Life table  
Predicted 14 35 40 42 57 
0.64 
>50% risk: 8% 
PPV: 30% Se: 13% 
NPV: 81% Sp: 93% Observed OCM
± 15 (12-20) 19 (17-22) 31 (27-37) 40 (31-48) 38 (30-46) 
Δ Quintiles were separately defined for each tool, with patients assigned to different quintiles based on the predicted risk from each tool.  
Bold font among numerical values indicates quintiles where 95% confidence intervals for cumulative incidence estimates for OCM (observed deaths) 
overlapped with the predicted OCM death rate 
α Observed all-cause mortality rates were determined utilizing Kaplan-Meier methods for all-cause mortality 
± Observed OCM rates were determined utilizing modified Kaplan-Meier methods for competing risks analysis (cumulative incidence distributions) 
>50% risk= % of patients assigned higher than 50% risk score 
PPV= positive predictive value 
NPV=negative predictive value 
Se= sensitivity 
Sp= specificity 
**performance measures for Social Security life tables are calculated with all-cause mortality, not other cause mortality 
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Table 3.4: Patient characteristics: secondary analysis sample (age 66+ group) 
 Total Prostate- Specific Death 
Other Cause 
Mortality Surviving 
No. of patients (%) 2854 116 (4) 648 (23) 2090 (73) 
Mean age at diagnosis 75.1 78.8 77.3 74.3 
Race/ethnicity (%)     
   White 2221 (78) 90 (78) 524 (81) 1607 (77) 
   Black 311 (11) 13 (11) 66 (10) 232 (11) 
   Hispanic/Asian/Pacific Islander or other 322 (11) 13 (11) 58 (9) 251 (12) 
CaPSURE Comorbidity Count (%)     
   0 730 (26) 24 (21) 118 (18) 588 (28) 
   1 937 (33) 24 (21) 184 (28) 729 (35) 
   ≥2 1187 (42) 68 (58) 346 (53) 773 (37) 
Charlson Comorbidity Index Score (%)     
   0 1582 (55) 50 (43) 259 (40) 1273 (61) 
   1 674 (24) 27 (23) 172 (27) 475 (23) 
   ≥2 598 (21) 39 (34) 217 (33) 342 (16) 
PCa Management     
   Conservative 1148 (40) 83 (71) 356 (54) 709 (34) 
   Radical Prostatectomy 300 (11) ~ 26 (4) 273 (13) 
   Radiation Therapy 1406 (49) ~ 266 (41) 1108 (53) 
~ exact n=,% not reportable per SEER-MHOS data use agreements  due to small cell size 
Mean follow-up time for this cohort was 7.2 years 
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Table 3.5: Comparison of predicted to observed percent deaths for three risk estimation methods: Social Security life tables, 
CaPSURE and PCOS tools in secondary analysis population (Age 66+) 
  
 
 
Risk Estimation Tool Risk  Type 
Percent 10-year Mortality by QuintileΔ of Risk (95% CI) Harrell’s  
c-index 
Performance 
Measures 
Quintile 1  Quintile 2 Quintile 3 Quintile 4 Quintile 5 
Social Security  
Life Table  
Predicted 29 37 45 56 77 
0.66 
>50% risk: 39% 
**PPV: 38% Se: 56% 
NPV: 81% Sp: 67% 
Observed All-
Cause Mortalityα 19 (16-22) 27 (23-30) 30 (25-35) 39 (34-44) 59 (53-65) 
Observed OCM± 17 (14-20) 23 (20-27) 26 (21-31) 33 (28-37) 49 (44-55) 
CaPSURE Nomogram  
Predicted 24 33 38 45 60 
0.68 
>50% risk: 13% 
PPV: 46% Se: 27% 
NPV: 81% Sp: 91% Observed OCM
± 14 (11-17) 24 (21-28) 24 (19-30) 36 (32-41) 58 (51-64) 
PCOS Life table  
Predicted 14 35 40 42 57 
0.65 
>50% risk: 8% 
PPV: 40% Se: 15% 
NPV: 79% Sp: 93% Observed OCM
± 15 (11-19) 23 (21-26) 36 (32-41) 44 (37-51) 46 (39-53) 
Δ Quintiles were separately defined for each tool, with patients assigned to different quintiles based on the predicted risk from each tool.  
Bold font among numerical values indicates quintiles where 95% confidence intervals for cumulative incidence estimates for OCM (observed deaths) 
overlapped with the predicted OCM death rate 
α Observed all-cause mortality rates were determined utilizing Kaplan-Meier methods for all-cause mortality 
± Observed OCM rates were determined utilizing modified Kaplan-Meier methods for competing risks analysis (cumulative incidence distributions) 
>50% risk= % of patients assigned higher than 50% risk score 
PPV= positive predictive value 
NPV=negative predictive value 
Se= sensitivity 
Sp= specificity 
**performance measures for Social Security life tables are calculated with all-cause mortality, not other cause mortality 
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Table 3.6: Validation of the CaPSURE nomogram predictors for 10-year other cause 
mortality 
 Original Model Estimatesα Validation: SEER-MHOS 10-year OCM Model Estimates 
 Predictors Hazard Ratio 95% CI p-value 
Hazard 
Ratio 95% CI p-value 
Age at diagnosis 
Number of comorbidities 
African American vs. white 
RT vs. RP# 
1.06 1.05-1.08 <0.001 1.06 1.02-1.09 <0.001 
1.23 1.15-1.32 0.015 1.35 1.22-1.48 <0.001 
1.34 1.03-1.73 0.03 0.88 0.59-1.32 0.545 
1.26 1.07-1.49 0.006 1.64 1.08-2.46 0.018 
α Kutikov A, et al. (2012). Evaluating prostate cancer mortality and competing risks of death in patients with 
localized prostate cancer using a comprehensive nomogram. Prostate Cancer and Prostatic Diseases, 
15(4), 374–9.  
 
The analysis for the CaPSURE Model was based on a subset of 1629 complete cases who underwent either 
RT or RP. Conservatively managed cases were excluded as the original Kutikov/CaPSURE model was 
developed without conservatively managed patients. 
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Supplement 3.A: Detailed methods utilized for approximating and modifying CaPSURE and 
PCOS risk estimation tool comorbidity assessments 
CaPSURE Nomogram: The CaPSURE comorbidity count could be approximated with 6 of 7 conditions 
available. There was no information available in SEER-MHOS on self-reported renal disease and there were 
no alternative mechanisms for assessing renal disease, thus this condition was left out of the “CaPSURE 
comorbidity count approximation.” The table below summarizes the overlap between the original tool 
definitions and approximations in this study.  
CaPSURE Tool Original Comorbidities SEER-MHOS Conditions Available and Utilized 
for “CaPSURE Comorbidity Count” 
Approximation  
Hypertension Hypertension 
Heart disease Acute myocardial infarct, congestive heart failure, 
angina, coronary artery disease, other heart disease 
Stroke Stroke, paralysis 
Diabetes Diabetes 
Lung disease Chronic obstructive pulmonary disease or 
emphysema 
Cancer Other prior cancers or developed within 1 year of 
PCa diagnosis 
Kidney disease Not available 
PCOS Life Tables: There was data available for 10 of 12 PCOS conditions utilized for the PCOS 
comorbidity count variable originally reported in the development manuscript for this tool. Data on bleeding 
gastrointestinal ulcers and cirrhosis were not available in SEER-MHOS. However, model performance 
estimates revealed that the OCM risk estimates generated utilizing a close approximation of the PCOS 
comorbidity count provided greater overestimation of patient mortality risk. Further, when the eight 
conditions available in SEER-MHOS which overlap with the Charlson Comorbdity Index (see table below) 
were substituted with Charlson weights in lieu of the PCOS comorbidity count approximation, the assigned 
predicted OCM rates were much closer to observed mortality in the SEER-MHOS population. Thus, the 
choice was made to utilize Charlson Index approximations for comorbidity assessments as described in the 
Methods section, as this optimized the PCOS life table performance in this population. The table below 
summarizes the differences between the methods.  
PCOS Tool Original 
Comorbidities 
SEER-MHOS Conditions Available  Overlapping Charlson Index 
Conditions Utilized for 
Comorbidity Approximation in 
Final Analysis 
Diabetes Diabetes Diabetes 
Chronic lung disease Chronic obstructive pulmonary 
disease or emphysema 
Chronic obstructive pulmonary 
disease 
Congestive heart failure Congestive heart failure Congestive heart failure 
Stroke Stroke, paralysis Stroke 
Myocardial infarction Acute myocardial infarction  Myocardial infarction 
Inflammatory bowel disease Inflammatory bowel disease Inflammatory bowel disease 
Angina/ chest pain Angina N/A 
Arthritis available but high prevalence N/A 
Hypertension available but high prevalence N/A 
Depression or anxiety available as SF-36 MCS but high 
prevalence with this definition 
N/A 
Bleeding gastrointestinal ulcer Not available Not available 
Cirrhosis Not available Not available 
  Other cancer 
  Paralysis 
53 
Chapter IV 
CHAPTER IV: SELF-REPORTED DATA IMPROVE PRETREATMENT 
PREDICTIONS OF THE RISK OF DEATH FROM OTHER CAUSES IN 
PATIENTS WITH LOCALIZED PROSTATE CANCER 
 
ABSTRACT 
Background: Accurate estimation of life expectancy is important for making appropriate 
treatment decisions for men with prostate cancer (PCa), the majority of whom will die of 
non-prostate causes. This study sought to develop an improved model for estimating 10-
year other cause mortality (OCM) risk utilizing an efficient combination of self-reported 
data from men newly diagnosed with localized PCa. 
Methods: 2,425 patients, age <80, newly diagnosed with clinical stage T1-T3a PCa from 
1998-2009, were identified from the Surveillance Epidemiology and End Results - 
Medicare Health Outcomes Survey database. Fine and Gray competing risks models for 
10-year OCM were fitted with PCa deaths as competing events. Candidate predictors 
included: age, sociodemographic characteristics, comorbid medical conditions, elements 
of the SF-36 Health Survey, and activities of daily living. Akaike’s Information Criterion 
(AIC) and Harrell’s c-index (range: 0.5-1.0) guided model selection, optimizing model fit 
and discrimination between individuals who live and who die. As a benchmark, model 
discrimination was compared to predictions from two currently available nomograms for 
estimating non-prostate mortality risk.  
Results: Over a median follow-up of 7.7 years, 76 men died of PCa-specific causes and 
465 died of other causes. The final competing risks model for 10-year OCM included age 
at diagnosis, self-report derived Charlson Comorbidity Index score, self-rated general 
health (excellent-good vs. fair vs. poor), smoking at diagnosis, and marital status 
(married vs. all other) as predictors. Discrimination between survivors and those dying of 
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OCM improved over available nomograms (c-index of 0.70 vs. 0.64/0.65). The five factor 
model performed as well as models that included more detailed assessments of self-
reported physical health, and activities of daily living.  
Conclusions: This limited set of five self-reported characteristics may aid in more 
accurately estimating OCM risk prior to treatment decision-making. 
 
BACKGROUND 
Accurate assessment of life expectancy is critical to enabling evidence-based 
treatment decision-making for the over 220,000 men diagnosed with prostate cancer 
(PCa) in the U.S. annually.1 Guidelines consistently recommend that clinicians assess 
patients’ life expectancy in the treatment decision-making process and reserve definitive 
treatment of localized tumors for men with at least a 10-year life-expectancy.7,9,53 These 
recommendations arise from documented risks of treatment-associated morbidity,9 and 
randomized clinical trial evidence demonstrating a lack of treatment benefit for 
individuals with follow-up of less than 8-10 years.76 For men with localized tumors the 
average risk of dying of PCa in the 10 years following diagnosis is less than 5%, 
regardless of treatment.10,11 In contrast, the risk of dying of non-prostate causes can 
range from as little as 6% to over 90% depending on an individuals’ age, health and 
social factors.10,12–15 Enabling clinicians to accurately determine non-prostate mortality 
risk is of high importance, especially given that currently a quarter to half of patients are 
likely overtreated, dying of non-PCa causes within 10 years of diagnosis.12 
Currently available prediction tools largely rely on age and comorbidity for 
assessing mortality risk.10,12,26,27 As Chapter III of this dissertation demonstrated, existing 
prediction tools are limited in their ability to accurately discriminate between individual 
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patients who will survive 10 years and those who will die of other causes,69 particularly 
among patients 65-80 years of age for whom life expectancy determinations may highly 
influence treatment decisions. These tools do not meet thresholds for reliably 
distinguishing between those likely to live and die in a clinical setting.72 There is, 
however, mounting evidence that additional self-reported factors have value in predicting 
other cause mortality (OCM) beyond comorbidity and age alone.27,33 This study sought to 
identify an optimal combination of self-reported data for pretreatment estimation of the 
risk of OCM in men newly diagnosed with localized PCa. 
 
METHODS 
Data Source 
This study utilized the Surveillance, Epidemiology, and End Results (SEER) - 
Medicare Health Outcomes Survey (MHOS) linked database which provides data on 
19,727 men diagnosed with PCa through 2009. Follow-up survival data are available 
through February 2013. The National Cancer Institute’s SEER cancer registry collects 
sociodemographic, tumor, and treatment data representative of 26% of the U.S. 
population.54 The Centers for Medicare & Medicaid Services’ (CMS) conducts the MHOS 
survey, annually collecting self-reported comorbidity and health behavior data from a 
sample of Medicare managed care plan participants across all of its plan offerings to 
monitor health outcomes with response rates of 64-72%.48 Medicare managed care 
participants represent roughly 19% of all Medicare beneficiaries. The complete details of 
the SEER-MHOS linkage and data collection methods have been previously described.48 
 
Study Population 
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Patients were selected if <80 years of age when newly diagnosed with PCa 
between January 1, 1998 and December 31, 2009, having completed an MHOS survey 
within the 3 years before their PCa diagnosis. Exclusion criteria included diagnosis of 
PCa on autopsy or death certificate or regionalized or metastasized tumors (stage > 
cT3a).  
Data Collected 
Age at diagnosis was determined from the SEER registry. Self-reported 
comorbidity data was available for the following conditions: hypertension; angina or 
coronary artery disease; myocardial infarction; other heart conditions; stroke; 
emphysema, asthma or chronic obstructive pulmonary disease (COPD); Crohn’s 
disease, ulcerative colitis, or inflammatory bowel disease; arthritis of the hip or knee; 
arthritis of the hand or wrist; sciatica; diabetes; any cancer other than skin cancer; 
paralysis or weakness on one side of the body. An approximated Charlson Comorbidity 
Index (CCI) score was generated utilizing Charlson weights for 8 self-reported conditions 
in MHOS (myocardial infarction, congestive heart failure, stroke, COPD, diabetes, 
inflammatory bowel disease, paralysis, other cancer), which overlap with conditions in 
the CCI.34 A crude count of available comorbid conditions was also assembled with 
conditions overlapping with prior OCM prediction tools.26 
Self-reported physical and mental health were measured with the SF-36 Health 
Survey (v1)42,43 which MHOS administered to participants before 2006 and the VR-12 
Health Survey,58 a shorter instrument with slight modifications, for men surveyed in 2006 
and after. From the surveys, a Physical Component Summary (PCS) score, which 
summarizes patients’ physical functioning, role limitations due to physical health, bodily 
pain and general health perceptions and a Mental Component Summary (MCS) score, 
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that summarizes patients’ vitality, social functioning, role limitations due to emotional 
health, and mental health, were generated. PCS and MCS were scored by MHOS with 
an algorithm that allows for comparing scores across different survey forms.59 Scores 
are normalized to a mean of 50 points in the general U.S. population with a standard 
deviation of 10 points, with higher scores representing better health.42,60 Additionally a 
single item, available in both surveys, assessing self-rated general health as excellent, 
very good, good, fair, or poor was utilized.  
MHOS also collected data on a number of self-reported activities of daily living. A 
prior MHOS report provided a scoring mechanism for a combination of 16 activities of 
daily living (ADL) and physical functioning (PF) items from the SF-36 Health Survey for 
the purposes of mortality prediction and case-mix adjustment, named the PF-ADL 
scale.77 This study modified the PF-ADL scoring to utilize only 8 items available across 
all MHOS survey forms (moderate activities physical functioning item and ADLs: 
climbing stairs, bathing, dressing, eating, getting out of a chair, walking, toileting). 
Scores are reported on a 0-100 point scale, with higher scores representing better 
health.  
Self-reported current smoking status (every day or some days) was determined 
from MHOS. Individuals who had unknown smoking status were categorized as non-
smokers, as exploratory analyses revealed they experienced survival similar to non-
smokers.  Education was categorized as “more than a high school education” or “high 
school education or less” to provide consistency with prior definitions.33 Race-ethnicity, 
reported in SEER, was categorized as white, black, Hispanic, Asian/Pacific Islander, and 
other. MHOS variables for self-reported data on marital status (married vs. all other), 
home ownership, and household income were also utilized.  
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Survival and Mortality Outcomes 
Survival and detailed cause of death were determined through the SEER portion 
of the dataset. Patients not experiencing death within 10 years of PCa diagnosis were 
censored at 10 years if followed ≥10 years after diagnosis, or at time of last SEER 
follow-up if followed <10 years. Patients who died were classified as having died of 
prostate-specific (PCSM) versus other causes; specific causes of OCM were confirmed 
using the SEER cause of death recode variable (codpub). Survival was calculated as the 
difference between the date of diagnosis and the date of death, or last SEER follow-up 
date for censored patients.  
Statistical Analysis 
Patient characteristics were compared among those dying of PCSM, OCM and 
survivors using one-way analysis of variance tests and chi-squared tests as appropriate. 
Overall cumulative incidence of 10-year OCM was computed utilizing modified Kaplan-
Meier methods that account for the competing risk of dying of PCSM. Fine and Gray 
competing risks models for 10-year OCM were fitted with self-reported pretreatment 
patient characteristics and with PCSM as the competing event.74 Akaike’s Information 
Criterion (AIC) and Harrell’s c-index were utilized to guide model selection to optimize 
model parsimony and discrimination between individuals who survived and died over the 
10 year follow-up period.65 Minimizing AIC helps to reduce information loss and accounts 
for the tradeoff between goodness-of-fit and model complexity, penalizing more complex 
models that do not substantially fit the data better. Harrell’s c-index (concordance index) 
assesses a model’s ability to discriminate between individuals who survive and die. The 
c-index measures whether pairs of patients with different risk profiles have expected 
relative outcomes; a pair is concordant if a person with lower predicted risk has not 
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experienced the event by the time a person with higher predicted risk has the event; a 
pair is discordant if the person with lower risk experienced the event sooner. A pair is not 
evaluable unless at least one in the pair experiences the event. The c-index is the 
number of concordant pairs divided by the number of concordant plus discordant pairs. 
Models that are no better than a flip of a coin in assigning risk and distinguishing 
between surviving and dying patients will have a c-index of 0.5; models that perfectly 
classify all patients’ risk from highest to lowest risk in the data set will receive a value of 
1.0.  
Candidate predictors of non-prostate mortality included age at diagnosis, 
comorbid medical conditions (a comorbidity count or as the approximated CCI), PCS, 
MCS, PF-ADL, self-rated general health, and sociodemographic variables (race, marital 
status, education level, household income).10,26,27,33,77 Interaction terms between age and 
comorbidity, comorbidity and general health, age and general health, and smoking and 
comorbidity were considered in the modeling process to evaluate potential effect 
modification.29 Risk scores were then generated from the final model utilizing the 
equation: cumulative risk of 10 year OCM = 1 – (baseline survival at 10 years)𝑒
(∑ 𝑥?̂?)
.  
SEER-MHOS death rates are lower than observed in most populations which 
may lead to systematic underestimation of mortality risk in other populations.12 To 
improve the generalizability of the final model risk estimates, the model was re-calibrated 
to an expected 10-year mortality rate of 36.9%, obtained by applying the Social Security 
life table age-matched 10-year all-cause mortality risk estimates (39.9%) in this 
population minus the roughly 3% prostate-specific mortality.71 Recalibration was 
achieved by reducing the baseline survival rate in the risk equation presented above, to 
achieve an overall predicted 36.9% death rate for the whole population.  
60 
Chapter IV 
As a performance benchmark, discrimination of the new model was compared to 
the discrimination of two currently available nomograms for predicting OCM risk (Table 
1.1).26,27 The first benchmark nomogram, developed in the CaPSURE database, was 
modified slightly for use in the SEER-MHOS data and utilized age, comorbidity count, 
radiotherapy or conservative management vs. radical prostatectomy, and race black vs. 
white for generating OCM predictions.26 Details of model adaptations are described in 
the methods of Chapter III of this dissertation. The other benchmark nomogram, 
developed by Hoffman et al. in the PCOS database, utilized age, race (categorized as 
Hispanic vs. non-Hispanic whites vs. black), and self-rated general health (excellent/very 
good/good/fair-poor) categorizations to predict OCM risk.27 Risk scores from each model 
were assigned to all eligible patients in the SEER-MHOS database with complete data 
and c-index values were calculated for each model. Neither nomogram’s c-index was 
reported in the original publications.26,27 
As a sensitivity analysis, the model performance was also evaluated in a sample 
of SEER-MHOS patients who were over age 66 at diagnosis, including patients over age 
80 who were excluded from the main analysis. Subject characteristics and methods for 
this sensitivity analysis are described in supplementary appendix 4.A.  
 
RESULTS 
Patient demographics 
Mean patient age at diagnosis was 73 years.  The majority of men (54%) had 
CCI scores of 0, ranging from 0-7 points, with 21% of the sample having scores of 2 or 
higher. Compared to surviving men, those who died of OCM were older, with higher 
comorbidity burden, worse PCS scores, worse general health, more likely to be smokers 
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at diagnosis and less often married. Full sample characteristics are summarized in Table 
4.1.  
Fine and Gray competing risks regression analysis 
Over a median follow-up of 7.7 years, 3.7% of the cohort died of PCa-specific 
causes and 24.3% of OCM. Median follow-up for survivors was 8.9 years (interquartile 
range 5.5-11 years). The combination of self-reported pretreatment factors with highest 
predictive value for death from other causes included age at diagnosis, self-reported 
CCI, self-rated general health (excellent to good vs. fair or poor), smoking at time of 
diagnosis, and marital status (married vs. all other) (Table 4.2). This model achieved a c-
index of 0.70 vs. 0.64 and 0.65 for estimates from the currently available comorbidity 
and self-rated health based nomograms, respectively.  
The five factors of age, CCI score, general health, smoking at diagnosis, and 
marital status performed as well as models that included more robust assessments of 
self-reported physical and mental health (PCS and MCS) and models that included 
activities of daily living (PF-ADL) (c-index was 0.70 for all tested variants with minimal 
differences in AIC). Other socioeconomic and race factors (education level, household 
income, homeownership) did not have significant associations with OCM when added to 
models that included age and CCI score, with the exception of being in the “other” race 
category, which did not have a clinically interpretable definition and represented a very 
small percentage (4%) of patients in the sample.  The models discriminated better 
between surviving and dying individuals when comorbidity was assessed with a CCI 
score approximation than with a crude comorbidity count. No significant interactions 
were observed, with the exception of poor general health and a CCI score of 7, which 
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applied to <11 individuals in the entire sample, and was left out of the final model, having 
limited applicability.  
Risk scores 
Table 4.3 demonstrates the range of obtained risk scores from the regression 
equation. Median predicted 10-year OCM risk was 20% (interquartile range 15-29%). 
Mortality risk estimates are also provided in a re-calibrated version for a higher expected 
death rate, obtained from the Social Security life tables (see Methods). This re-
calibration provides a simulation of how risk estimates may have varied if the model 
were fitted in a population that experienced a higher death rate. When the estimates 
were re-calibrated, the median predicted 10-year OCM risk rose to 33% (interquartile 
range 25-44%).  
Table 4.4 demonstrates predictions for five clinical scenarios, where the example 
patients have sequentially poorer health and are higher risk in each example. The 
examples demonstrate a much wider mortality risk spread than found in our data, which 
could be obtained if the model were utilized in a population with greater comorbidity 
burden, poorer health behaviors, and worse general health. In Table 4.4, estimates from 
the primary analysis in this study are listed as “low range” risk estimates, while estimates 
from the re-calibrated model are listed as the “high range” risk estimates.  
Sensitivity analysis 
The model discrimination improved slightly when patients over 80 were added (c-
index: 0.72), and continued to outperform previous prediction models which achieved c-
index values of 0.68 and 0.69 in the population including patients >80 (supplement 4.A). 
The effects of individual predictors remained largely the same when the model was 
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refitted in this older population, indicating that the model should apply to older patients 
as well. 
 
DISCUSSION 
 This study developed a prognostic model for 10-year OCM risk, identifying a set 
of five pretreatment self-reported patient characteristics for mortality prediction, which 
performed as well as more detailed and burdensome evaluations of health. While 
accurately predicting OCM risk for an individual patient remains challenging, this model 
better discriminated between individuals dying and surviving, as compared to currently 
available risk estimation tools. Model estimates were also re-calibrated to age-matched 
general U.S. population death rates to improve the generalizability of predictions from 
this study.  By relying on self-reported pre-treatment data (age, comorbidities, rating of 
general health, smoking, marital status), this study provides a simple, reproducible 
method for OCM risk estimation that may aid in facilitating shared decision making 
surrounding appropriately aggressive therapy for PCa. 
 There are a number of existing tools available for estimating the risk of dying of 
other causes.10,12,26,27,78 Despite the availability of these tools there has been very limited 
adoption of these risk calculators and life tables in clinical practice; less than a quarter of 
PCa specialists utilize such tools.16 Several factors limit the utility of existing tools and 
the likelihood of clinical uptake. As demonstrated in Chapter III of this dissertation, the 
estimated risk of OCM can vary widely depending on which tool is utilized and models 
have limited to poor discrimination between individuals likely to die of OCM and those 
likely to survive 10 years.69 The variability in risk estimates may be due to differences in 
death rates in the populations that these tools were developed in and due to differences 
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in the specification of model inputs. For example, self-reported vs. claims-based 
assessments of comorbidity can yield widely different estimates of the prevalence of a 
particular condition, affecting the estimated risk score. Further, the thresholds at which 
conservative management strategies should be adopted are poorly defined. This 
complicates the interpretability of a particular percentage of estimated OCM risk and 
limits the clinical utility of these tools. Finally, existing tools are in the form of life tables 
or nomograms which are less user-friendly than online electronic interfaces. This study 
sought to address these key limitations. The final risk model developed in this 
dissertation is currently being adapted as an online risk calculation tool. 
 The final model risk factors selected in this study: age, comorbidity, self-reported 
health, marital status, and smoking, have all been shown to be important predictors of 
mortality and life-expectancy.10,12,26,27,33,77,78 This model is the first to combine these 
factors in a prognostic calculator for 10-year OCM risk. Risk factors were obtained from 
self-report, which can be easily reproduced in any clinical setting.  
Further, Chapter III of this dissertation demonstrated that SEER-MHOS death 
rates are among the lowest of all available cohorts of patients.10,12,26 This would lead to 
underestimation of mortality risk should this model be applied to higher risk patient 
populations. To address this limitation, risk estimates were re-calibrated for higher 
expected death rate from the general U.S. male population Social Security estimates. All 
risk scores are presented with a low range and a high range estimate to reflect the 
potential variability in estimated risk across populations.   
Risk scores can be interpreted based on the percentile that the risk score falls in 
relative to risk estimates from this population-based study (provided in Table 4.3). 
Selection of appropriately aggressive therapy may be achieved by more thoroughly 
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discussing the risks and benefits of definitive therapies, and conservative management 
alternatives, with patients in the highest risk categories (who may be expected to die 
within 10 years of diagnosis). For example, a 75 year-old, married, non-smoker, who 
rates his health as “good” and has one Charlson comorbidity point would be expected to 
have a 20% to 32% 10-year OCM risk which places him in the middle 50% of OCM risk 
among patients in the SEER-MHOS data. In this case, the risk score is inconclusive, and 
does not clearly promote a particular management strategy. In contrast, a 70 year old, 
married, smoker, with one Charlson comorbidity point and a self-rating of health as “fair” 
has a higher 38 to 56% predicted 10-year OCM risk, and falls in the highest 75% risk 
group of all patients (Table 4.3). More careful consideration of conservative 
management alternatives with such a patient may promote selection of appropriately 
aggressive therapy. To promote ease of use, an electronic risk calculation interface is 
provided to accompany this manuscript and ease the burden of risk estimation. 
While more detailed assessments of health impairment were considered in the 
modeling process these variables did not improve upon the five factor models’ 
predictions in terms of discriminating between those who survived and died. Other 
factors considered included self-rated physical and mental health, measured as PCS 
and MCS scores, activities of daily living, and a more extensive comorbidity count. As 
these more burdensome assessments of self-reported health, as well as other 
sociodemographic factors, did not improve upon the model performance a final model 
was selected with the easiest to obtain and universally reproducible predictors.  
This work has several limitations.  This study only accounted for a limited set of 8 
of the Charlson Comorbidity Index conditions, and thus there may be several conditions 
such as end stage renal disease, liver failure, and peptic ulcer disease, among others 
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which contribute to mortality risk but could not be accounted for in the SEER-MHOS 
data. This may limit the model’s ability to discriminate between individuals likely to 
survive vs. die, to the extent the missing conditions provide information not already 
incorporated in the five model factors (such as general health). Overall, the model’s 
performance achieved modest clinical utility for discrimination with c-index values 
>0.70.72 While discrimination improved over prior models, the gains were also relatively 
modest. However, it should be noted that a third to a half of patients with PCa die of 
events which may be relatively unpredictable over 10 years (e.g., subsequent 
development of other non-PCa cancers, acute cardiac events and stroke) with a single 
set of baseline data.2,33 Thus there may be inherent limits to the extent to which 
prognostic models such as the one developed in this study can accurately predict 10-
year mortality risk and discriminate between all individuals who will die and survive. This 
model was also estimated in patients <80, as clinical decisions regarding treatment are 
most relevant in that population, which may limit the generalizability of risk estimates to 
older samples. However sensitivity analysis in older patients suggested the model 
generalizes well when including older individuals.  
 
CONCLUSIONS 
This study provides a prognostic model which utilizes a simple set of five 
pretreatment self-reported characteristics that may better identify patients at higher risk 
of non-PCa mortality than age and comorbidity based assessments alone. 
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Table 4.1: Patient characteristics 
 Total 
Prostate- 
Specific 
Death 
Other Cause 
Mortality Surviving p-value 
No. of patients (%) 2425 76 (3) 465 (19) 1884 (78) - 
Mean age at diagnosis 72.9 74.5 73.8 72.6 <0.001 
Race/ethnicity (%)      
   White 1879 (77) 57 (75) 371 (80) 1451 (77) 0.282 
   Black 290 (12) ~ 55 (12) 223 (12)  
   Hispanic/Asian/Pacific Islander or other 256 (11) ~ 39 (8) 210 (11)  
Charlson Comorbidity Index Score (%)     <0.001 
   0 1326 (54) 31 (40) 177 (38) 1118 (59)  
   1 586 (24) 18 (24) 130 (28) 438 (23)  
   ≥2 513 (21) 27 (35) 158 (34) 328 (17)  
Marital Status      
   Married vs. all other (%) 1695 (70) 48 (63) 292 (63) 1355 (72) <0.001 
Smoker at diagnosis (%) 301 (12) 18 (24) 86 (18) 197 (10) <0.001 
Patient Reported Functioning and Wellbeing      
   PCS (mean, SD) 43.5 (10.9) 41.2 (11.6) 40.1 (11.1) 44.4 (10.4) <0.001 
   MCS (mean, SD) 53.3 (9.4) 49.3 (10.7) 51.5 (10.4) 53.9 (8.9) <0.001 
   Physical Functioning - ADL Index (mean, SD)± 87.8 (15.5) 83.1 (17.6) 83.4 (16.9) 89.2 (14.8) <0.001 
   General Health (Fair or Poor) (n, %) 521 (22) 23 (30) 169 (37) 329 (18) <0.001 
Tumor Grade (%)     <0.001 
   Well to Moderately Differentiated 1630 (67) 30 (39) 338 (73) 1262 (67)  
   Poorly Differentiated or Unavailable* 795 (33) 46 (61) 127 (27) 622 (33)  
Tumor Clinical T-Stage (%)     <0.001 
   cT1 1,193 (49) 20 (26) 227 (49) 939 (50)  
   cT2 819 (34) 34 (45) 136 (29) 649 (34)  
   cT1/T2 or T3a or Unavailable** 413 (17) 22 (29) 102 (22) 296 (16)  
Primary Prostate Cancer Management (%)     <0.001 
   Conservative 794 (33) 46 (60) 197 (42) 551 (29)  
   Radical Prostatectomy 323 (13) ~ 28 (6) 294 (16)  
   Radiation Therapy 1308 (54) 29 (38) 240 (52) 1039 (55)  
~ cell size <11 individuals for some sub-categories, exact n=,% not reportable per SEER-MHOS data use agreements; the 
race variable was utilized as five levels in all analyses, including white, black, Hispanic, Asian-Pacific Islander, or other. 
*The small percentage of ungraded tumors were not reported individually in this table due to cell size reporting limitations and 
represented <3% of the total sample. 
**cT3a tumors contributed less than 2% to all categories; exact numbers were not reportable per SEER-MHOS data use 
agreements. Those without detailed cT-stage available (<3% of the sample) did not have regionalized/metastasized tumors, 
as confirmed by other SEER staging variables. 
±PF-ADL is scored on a 0-100 point scale with 0 being worse and 100 being best and is not normalized to a mean of 50 points 
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Table 4.2: Final adjusted Fine and Gray proportional hazards model for 10-year other cause mortality 
Predictor ?̂? 
Sub Hazard 
Ratio 
95% Confidence 
Interval Z-Score 
p-value for 
SHR 
Age at diagnosis (1 year increments) 0.078 1.08 1.06-1.11 6.44 <0.001 
Charlson Comorbidity Index Score 0.197 1.21 1.14-1.30 6.04 <0.001 
Self-rated general health      
   Poor vs. (excellent/very good/good) 1.010 2.75 1.83-4.13 5.47 <0.001 
   Fair vs. (excellent/very good/good) 0.623 1.86 1.49-2.33 4.84 <0.001 
Smoker at diagnosis 0.530 1.70 1.32-2.18 4.15 <0.001 
Marital status (all other vs. married) 0.307 1.36 1.12-1.66 3.04   0.002 
Baseline Survival: 0.99948996 
10-Year Overall Cumulative Incidence of Non-Prostate Mortality: 24.307% 
Model Harrell’s c-index: 0.701 
Over the observation period, the total number of OCM deaths =465. Total PCSM deaths=76  
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Table 4.3: Range of 10-year other cause mortality risk predictions from competing risks 
model and recalibration to higher risk patient data 
 
  Mean Predicted % 10-Year  Non-Prostate Mortality Risk 
Risk Group SEER-MHOS Data Social Security Life Table Re-calibrated 
Lowest 10% 12 20 
Lowest 25% 15 25 
Median Risk  20 33 
Highest 75% 29 44 
Highest 90% 42 61 
 
Risk scores were calculated as 1-(base survival)^(exp(Σ?̂?x)) 
Base survival was 0.99948996 for the SEER-MHOS data calculations and 0.999115237 for the 
Social Security life table re-calibrated estimates. Σ?̂?x can be calculated as the sum of the (?̂? 
presented in table 4.2 times the value for the covariate).  
 
Table 4.4: Sample clinical scenarios with increasing 10-year other cause mortality risk 
  
   
10-Year Other Cause 
Mortality Risk (%) 
Case Risk Case Description 
Age at 
Diagnosis 
Low 
Range 
Risk 
Estimate* 
High 
Range 
Risk 
Estimate* 
Lowest 
A non-smoker who is married, 
rates health as “good”  
with CCI score of 0 
65 8 13 
70 12 19 
75 17 27 
80 24 37 
Lower 
A non-smoker who is married, 
rates health as “good”,  
with CCI score of 1 
65 10 16 
70 14 23 
75 20 32 
80 28 43 
Moderate 
Smoker who is married, rates 
heath as “fair”,  
with CCI score of 1 
65 25 43 
70 38 56 
75 50 70 
80 65 84 
Moderate 
High 
Smoker who is married, rates 
health as “poor”,  
with CCI score of 2 
65 44 63 
70 57 77 
75 72 89 
80 85 96 
High 
Smoker who is unmarried, rates 
health as “poor”,  
with a CCI score of 3 
65 61 81 
70 76 91 
75 88 97 
80 95 99 
*Low range risk estimates are derived from SEER-MHOS model, high range estimates are derived 
from the Social Security life table re-calibrated model. 
Risk scores were calculated as 1-(base survival)^(exp(Σ?̂?x)) 
Base survival was 0.99948996 for the SEER-MHOS data calculations and 0.999115237 for the 
Social Security life table re-calibrated estimates. Σ?̂?x can be calculated as the sum of the (?̂? 
presented in Table 4.2 times the value for the covariate). 
CCI= Charlson Comorbidity Index 
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Supplementary Appendix 4.A: Refitting of prediction model in patients age 66 and older 
Secondary analyses included refitting of the final regression model in patients age 66 and older at prostate 
cancer diagnosis in order to assess the performance of risk estimates in a population that included older 
patients. Patient characteristics are detailed in Table 4.A.2. The final model identified in the primary sample 
was refitted in this older sample to evaluate whether variables performed differently when patients over 80 
were included in the sample and to assess to what extent model discrimination changed by including 
individuals with a high probability of death. The performance of the benchmark models was also re-
assessed in this population. Results of these analyses are reported in Table 4.A.2.  
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Supplemental Table 4.A.1: Patient characteristics: sensitivity analysis (age 66+ group) 
 Total Prostate- Specific Death 
Other Cause 
Mortality Surviving p-value 
No. of patients (%) 2854 116 (4) 648 (23) 2090 (73) - 
Mean age at diagnosis 75.1 78.8 77.3 74.3 <0.001 
No. race/ethnicity (%)      
   White 2221 (78) 90 (78) 524 (81) 1607 (77) 0.09 
   Black 311 (11) 13 (11) 66 (10) 232 (11)  
   Hispanic/Asian/Pacific Islander or other 322 (11) 13 (11) 58 (9) 251 (12)  
Charlson Comorbidity Index Score (%)     <0.001 
   0 1582 (55) 50 (43) 259 (40) 1273 (61)  
   1 674 (24) 27 (23) 172 (27) 475 (23)  
   ≥2 598 (21) 39 (34) 217 (33) 342 (16)  
Marital Status      
  Married vs. all other (%) 1948 (68) 69 (59) 390 (60) 1489 (71) <0.001 
Smoker at diagnosis (%) 301 (12) 18 (24) 86 (18) 197 (10) <0.001 
Patient Reported Functioning and Wellbeing      
   PCS (mean, SD) 43.5 (10.9) 41.2 (11.6) 40.1 (11.1) 44.4 (10.4) <0.001 
   MCS (mean, SD) 53.3 (9.4) 49.3 (10.7) 51.5 (10.4) 53.9 (8.9) <0.001 
   Physical Functioning - ADL Index (mean, SD)± 87.8 (15.5) 83.1 (17.6) 83.4 (16.9) 89.2 (14.8) <0.001 
   General Health (Fair or Poor) (n, %) 521 (22) 23 (30) 169 (37) 329 (18) <0.001 
Tumor Grade     <0.001 
   Well to Moderately Differentiated 1833 (64) 30 (39) 338 (73) 1351 (65)  
   Poorly Differentiated or Unavailable* 1021 (36) 46 (61) 127 (27) 739 (35)  
Tumor Clinical T-Stage     <0.001 
   cT1 1,372 (48) 37 (32) 302 (47) 1033 (49)  
   cT2 981 (34) 46 (39) 191 (29) 744 (36)  
   cT1/T2 or T3a or Unavailable** 501 (18) 33 (28) 155 (24) 313 (15)  
Prostate Cancer Management      
   Conservative 1148 (40) 83 (71) 356 (54) 709 (34) <0.001 
   Radical Prostatectomy 300 (11) ~ 26 (4) 273 (13)  
   Radiation Therapy 1406 (49) ~ 266 (41) 1108 (53)  
~ cell size <11 individuals for some sub-categories, exact n=,% not reportable per SEER-MHOS data use agreements; the race variable was 
utilized as five levels in all analyses, including white, black, Hispanic, Asian-Pacific Islander, or other. 
Mean follow-up time for this cohort was 7.2 years 
*The small % of ungraded tumors were not reported individually in this table due to reporting limitations and represented <3% of the total sample. 
**cT3a tumors contributed less than 2% to all categories; exact numbers were not reportable per SEER-MHOS data use agreements. Those 
without detailed cT-stage available (<3% of the sample) did not have regionalized/metastasized tumors, as confirmed by other SEER staging 
variables.  
±PF-ADL is scored on a 0-100 point scale with 0 being worse and 100 being best and is not normalized to a mean of 50 points 
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Supplemental Table 4.A.2: Final adjusted Fine and Gray proportional hazards model for 10-year other cause mortality in men >66 
years of age 
Predictor ?̂? 
Adjusted Sub 
Hazard Ratio 
95% Confidence 
Interval Z-Score 
p-value for 
Adjusted SHR 
Age at diagnosis (1 year increments) 0.079 1.08 1.07-1.10 10.93 <0.001 
Charlson Comorbidity Index Score 0.199 1.22 1.15-1.29 6.81 <0.001 
Self-rated general health      
   Poor vs. (excellent/very good/good) 0.709 2.03 1.37-3.00 3.55 <0.001 
   Fair vs. (excellent/very good/good) 0.465 1.59 1.32-1.92 4.81 <0.001 
Smoker at diagnosis 0.536 1.71 1.37-2.13 4.78 <0.001 
Marital status (all other vs. married) 0.275 1.32 1.11-1.56 3.20 0.001 
Baseline Survival: 0.999486195 
10-Year Overall Cumulative Incidence of Non-Prostate Mortality: 28.367% 
Model Harrell’s c-index: 0.724  
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CHAPTER V: DISCUSSION AND CONCLUSIONS 
 
This dissertation characterizes the need for OCM risk estimation in older men 
newly diagnosed with localized PCa and informs efforts to utilize risk estimation tools 
to better identify patients most likely to benefit from aggressive treatment vs. those 
who may not. Nearly a quarter of older men who were primarily treated with 
radiotherapy were overtreated for their PCa. Health factors indicative of a shorter life 
expectancy had little to no association with radiotherapy assignment, suggesting a 
need to more carefully assess these factors prior to treatment. However, existing 
tools for estimating patients’ mortality risk require improvement before clinicians can 
rely on their estimates to make better individualized treatment decisions. A new risk 
model developed here, with age, comorbidity, self-rated health, smoking, and marital 
status predictors improved upon prior models’ performance for individualized OCM 
risk estimation, more accurately discriminating between individuals who die and 
those who do not. While this new model may aid clinicians in better assessing 
patients’ OCM risk, a large percent of OCM deaths remain difficult to predict and 
future gains in model performance are only likely if improved predictors for these 
events become available.  
Overtreatment and improving patient selection for radiotherapy  
 Evidence from this dissertation and multiple recent studies now demonstrate 
that PCa overtreatment among older men is mostly attributable to overtreatment of 
lower-risk tumors with radiotherapy.12,14,24 This is primarily due to radiotherapy being 
far more common among older men than radical prostatectomy (54% vs. 13%, 
respectively) and because men undergoing radiotherapy are far more likely to die of 
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OCM in the 10 years following diagnosis than men treated with prostatectomy. It also 
is clear that health factors play a very different role in the selection of patients for 
radical prostatectomy vs. radiotherapies.24 The lack of association between health 
factors and radiotherapy assignment indicates that there is a clear need for 
systematic consideration of these factors prior to treatment. Anecdotal evidence from 
clinicians suggests that older patients are often considered for radiotherapy as they 
are deemed less optimal surgical candidates.12 Among these patients, the use of 
prediction tools will be especially important for separating those likely to die of OCM 
within 10 years from those who will not. 
 This dissertation also revealed that overtreatment rates among older men 
were much lower than previously suggested, although they remain substantial.15 
Previous studies have reported that up to 54-67% of older men with comorbidities 
may be overtreated,12,22 however population-based assessments of the overall rates 
of overtreatment among radiotherapy and prostatectomy treated patients have not 
yet been reported.12,14,15,22 In the present study, 23% of men died of OCM over the 10 
years following radiotherapy treatment, while only 12% of radical prostatectomy 
treated men experienced OCM over the same period. This is the first study to report 
observed average 10-year OCM rates by treatment type among older men in the 
U.S. At the aggregate level, it appears that overtreatment rates are substantially 
lower than previously suggested. Differences may in part be due to the fact that 
some prior studies predicted 10-year OCM risk as opposed to reporting observed 
cumulative incidences, potentially overestimating mortality risk and thus 
overtreatment.22 However, it also remains possible that the overtreatment rates 
reported here are somewhat biased downward due to the population of men studied. 
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Medicare managed care plan participants are of better health than other men of 
similar age, and thus less likely to experience OCM.66 Nonetheless, the substantial 
rate of overtreatment among radiotherapy treated patients reported here highlights 
the need for systematic evaluation of health prior to treatment.  
Limitations of current mortality risk estimation tools 
 While there is a need for accurate assessment of OCM in a pre-treatment 
clinical setting, available tools have limited clinical utility. This dissertation’s 
evaluation of existing mortality prediction tools for men with PCa revealed that 
current risk estimation tools have two primary flaws that limit their applicability in a 
clinical setting; the risk estimates provided by the model vary when applied in 
different populations, often providing overestimates of true OCM risk, and existing 
models are limited in their ability to distinguish between patients who will die and 
those who will not. Current clinical care guidelines recommend that clinicians utilize 
Social Security life table derived estimates of 10-year mortality risk for estimating life 
expectancy.9 However these estimates significantly over-predicted mortality risk in 
this cohort of men with PCa and had almost no utility at the individual patient level in 
discriminating between individuals who died and those who did not. Thus, the 
findings in this study should caution clinicians against using Social Security-based 
mortality estimates for estimating life expectancy for their patients with PCa. The 
OCM risk estimation tools, which incorporated comorbidity as a predictor, performed 
better by both measures but still below thresholds for making clinically reliable 
distinctions between individual patients’ risk. Thus, additional predictors, beyond age 
and comorbidity alone, are needed for improving risk predictions.  
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Self-rated health and sociodemographic factors improve predictions 
 The addition of self-rated health, smoking status and marital status to age 
and comorbidity predictors improved risk estimates. These factors capture additional 
information that is distinct from either age or comorbidity and improve the ability to 
discriminate between individual patients who will die versus those who will not. Each 
of these factors are well established predictors of mortality risk.27,33,37,41,77,79 While 
these may appear to be a limited set of predictors, the final risk estimation model 
presented in Chapter IV performed as well as models which included more 
burdensome evaluations of health such as multiple activities of daily living and more 
comprehensive assessments of patient-reported health from the SF-36 and VR-12 
health surveys. 
 The prediction model developed in this dissertation has the advantage of 
relying exclusively on self-reported data for OCM risk estimation. These variables are 
easy to obtain in any clinical setting. For example, the self-rated health variable is a 
simple five level rating of overall general health from excellent to poor; questions 
about current smoking status at diagnosis and whether the individual is married or 
not are equally low-burden to obtain. Comorbid conditions are limited to a finite 
number of conditions that can also be rapidly obtained.  
This information can easily be integrated to generate OCM risk estimates with 
the risk estimation tool developed in this dissertation. The tool provides a range of 
risk estimates to illustrate the potential variability in estimated risk between different 
populations of patients, intended to improve the generalizability of the risk estimates. 
Clinicians can see that a 70 year old married, non-smoking man, who has a CCI 
score of 1 and rates his health as fair may have a 48-67% risk of OCM, for example. 
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This addresses one of the main limitations of prior models, which provide single point 
estimates of risk that can often over-or under-predict OCM risk. This dissertation 
provides a low-range estimate using the SEER-MHOS data and re-calibrated 
estimates to match death rates expected for age-matched males in the U.S. general 
population as a higher-range OCM risk estimate. Risk estimates can be interpreted 
in relation to the distribution of risk in the population, placing the example patient 
above into the highest 90% of OCM risk and suggesting that this patient would not 
benefit from definitive PCa treatment.  
Limitations to prediction: the predictable vs. unpredictable 
 Many men with PCa go on to die of medical conditions that were not 
identified at the time of PCa diagnosis. Up to a quarter of men with PCa die of other 
cancers, most of which are diagnosed after their PCa.2,33 Another quarter of deaths 
in men with PCa are attributable to cardiac causes, many of which may acutely lead 
to death such as myocardial infarction, endocarditis, or are conditions which often 
lead to a demise in <10 years (such as heart failure). 2,33 The lack of good predictors 
for many causes of death, as well as the subsequent development of diseases not 
present at baseline, limits the extent to which perfect discrimination between patients 
who will die from those who survive 10 years can be achieved. It is difficult to predict 
deaths from these causes in the absence of information about these conditions. 
Perhaps more complex models that predict the likelihood of developing these 
diseases and incorporates that risk in OCM risk estimation would be of benefit. 
However, there are inherent limitations to predicting the occurrence of other cancers 
as most are due to unexplained random variation, and our ability to predict the acute 
cardiac events that lead to death is also relatively limited.80 Ultimately, predicting an 
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outcome such as OCM, which is influenced by many factors, at such a distant end 
point (10 years), during decades of life where health can change rapidly, may have 
inherent limitations. 
Yet despite these limitations, this dissertation demonstrated that clinicians are 
in fact relatively capable of selecting healthy patients with over 10-year life 
expectancy for treatment. This was clearly true for patients treated with radical 
prostatectomy, who died of OCM at a relatively low rate. This is likely largely driven 
by the fact that younger men are selected for radical prostatectomy; very few men 
over the age of 75 undergo this surgery.12 Furthermore, all of the measured health 
factors also appear to influence assignment to radical prostatectomy including 
comorbidity burden, physical health, and smoking. Thus, consideration of these 
factors in addition to age likely does achieve the goal of reducing overtreatment by 
selecting patients most likely to have over a 10-year life expectancy. Despite the 
flaws that some current tools may have in providing optimally precise risk estimates, 
they may promote discussions surrounding patients’ age and health and treatment 
risks and benefits and thereby help reduce the reflex to treat “cancer,” despite its 
indolent nature.11,81  
The future of OCM risk estimation 
As the collection of patient-reported health data becomes more prevalent and 
is better integrated into the clinical electronic medical record, future OCM prediction 
models may benefit from the integration of these types of data. Were a 
comprehensive electronic medical record available, with automatically generated 
comorbidity scoring information, and automated algorithms for predicting the risk of 
developing conditions associated with mortality (e.g. acute myocardial infarction), 
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future OCM risk prediction tools could harness these inputs. This may provide richer 
baseline health information than is currently available by just utilizing the presence or 
absence of particular medical conditions at baseline. There also is a wealth of 
additional patient-reported health information that can help us to better understand 
comorbidity. Patient report of disease impact and severity may provide a mechanism 
for distinguishing patients at higher risk of death from particular conditions.82 Future 
tools may be able to move beyond static assessments of the presence or absence of 
a condition and current ratings of health, and may be able to predict the development 
of comorbidities, which are difficult to comprehensively assess with the current types 
of databases available for generating prediction models.  
 
CONCLUSIONS 
 Overtreatment of older men with PCa is primarily due to definitive treatment 
with radiotherapy and may be reduced by reserving treatment for patients with lower 
comorbidity burden, better physical health and non-smokers. Implementation of 10-
year OCM risk estimation tools in pre-treatment decision-making may aid in reducing 
overtreatment by promoting consideration of these health factors. Existing age and 
comorbidity-based tools for 10-year OCM risk estimation are improved upon by the 
addition of self-reported health, marital and smoking status at diagnosis. This set of 
five pretreatment self-reported characteristics may better identify patients who will 
die of OCM and those who will not.  
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